This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-let-7b-5p | AIFM1 | 0.13 | 0.6518 | 0.08 | 0.68492 | miRNATAP | -0.14 | 0.00399 | NA | |
2 | hsa-let-7i-5p | AIFM1 | -0.19 | 0.47734 | 0.08 | 0.68492 | miRNATAP | -0.21 | 0.00013 | NA | |
3 | hsa-miR-125a-5p | AIFM1 | -0.31 | 0.3708 | 0.08 | 0.68492 | miRanda | -0.11 | 0.00731 | NA | |
4 | hsa-miR-125b-5p | AIFM1 | 0.4 | 0.2546 | 0.08 | 0.68492 | miRNATAP | -0.15 | 0.00022 | NA | |
5 | hsa-miR-145-5p | AIFM1 | -1.16 | 0.00337 | 0.08 | 0.68492 | miRNATAP | -0.08 | 0.02942 | 20332243 | Artificial overexpression of miR145 by using adenoviral vectors in prostate cancer PC-3 and DU145 cells significantly downregulated BNIP3 together with the upregulation of AIF reduced cell growth and increased cell death |
6 | hsa-miR-155-5p | AIFM1 | -1.43 | 0.00781 | 0.08 | 0.68492 | miRNAWalker2 validate | -0.08 | 0.00165 | NA | |
7 | hsa-miR-199a-5p | AIFM1 | -0.21 | 0.63598 | 0.08 | 0.68492 | miRanda | -0.17 | 0 | NA | |
8 | hsa-miR-125b-5p | AKT1 | 0.4 | 0.2546 | 0.04 | 0.7925 | miRNAWalker2 validate; miRTarBase | -0.11 | 0.0004 | NA | |
9 | hsa-miR-22-3p | AKT2 | 0.02 | 0.94029 | -0.15 | 0.46571 | mirMAP | -0.15 | 0.03865 | NA | |
10 | hsa-miR-326 | AKT2 | -0.75 | 0.13947 | -0.15 | 0.46571 | miRanda | -0.06 | 0.03378 | NA | |
11 | hsa-miR-106b-5p | AKT3 | -0.81 | 0.00943 | -0.53 | 0.25156 | miRNATAP | -0.54 | 0 | NA | |
12 | hsa-miR-17-3p | AKT3 | -0.07 | 0.78643 | -0.53 | 0.25156 | miRNATAP | -0.52 | 9.0E-5 | NA | |
13 | hsa-miR-17-5p | AKT3 | -0.67 | 0.04231 | -0.53 | 0.25156 | TargetScan; miRNATAP | -0.47 | 1.0E-5 | NA | |
14 | hsa-miR-181b-5p | AKT3 | 0.25 | 0.56352 | -0.53 | 0.25156 | miRNATAP | -0.16 | 0.03866 | NA | |
15 | hsa-miR-20a-5p | AKT3 | -0.39 | 0.26959 | -0.53 | 0.25156 | miRNATAP | -0.47 | 0 | NA | |
16 | hsa-miR-29a-3p | AKT3 | -0.39 | 0.22665 | -0.53 | 0.25156 | miRNATAP | -0.36 | 0.0009 | NA | |
17 | hsa-miR-29b-3p | AKT3 | -0.39 | 0.34358 | -0.53 | 0.25156 | miRNATAP | -0.27 | 0.00119 | 26512921 | MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3 |
18 | hsa-miR-29c-3p | AKT3 | -0.13 | 0.74361 | -0.53 | 0.25156 | miRNAWalker2 validate; miRNATAP | -0.17 | 0.03964 | NA | |
19 | hsa-miR-335-3p | AKT3 | -0.5 | 0.22325 | -0.53 | 0.25156 | mirMAP | -0.3 | 0.00029 | NA | |
20 | hsa-miR-362-3p | AKT3 | -1.21 | 0.01257 | -0.53 | 0.25156 | miRanda | -0.27 | 0.00013 | NA | |
21 | hsa-miR-362-5p | AKT3 | -0.73 | 0.11206 | -0.53 | 0.25156 | PITA; TargetScan; miRNATAP | -0.3 | 5.0E-5 | NA | |
22 | hsa-miR-374b-5p | AKT3 | -0.94 | 0.0014 | -0.53 | 0.25156 | mirMAP | -0.26 | 0.02459 | NA | |
23 | hsa-miR-502-3p | AKT3 | -0.73 | 0.03618 | -0.53 | 0.25156 | miRNATAP | -0.35 | 0.00041 | NA | |
24 | hsa-miR-502-5p | AKT3 | -1.02 | 0.03949 | -0.53 | 0.25156 | PITA; miRNATAP | -0.24 | 0.00053 | NA | |
25 | hsa-miR-505-3p | AKT3 | -1.26 | 0.00026 | -0.53 | 0.25156 | mirMAP | -0.26 | 0.00822 | 22051041 | We also find that Akt3 correlate inversely with miR-505 modulates drug sensitivity in MCF7-ADR |
26 | hsa-miR-577 | AKT3 | 0.81 | 0.31426 | -0.53 | 0.25156 | mirMAP | -0.15 | 0.00024 | NA | |
27 | hsa-miR-93-5p | AKT3 | -0.47 | 0.13146 | -0.53 | 0.25156 | miRNATAP | -0.56 | 0 | NA | |
28 | hsa-miR-18a-5p | ATM | -1.18 | 0.00436 | -0.78 | 0.04275 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.15 | 0.03076 | 23437304; 25963391; 23857602; 23229340 | MicroRNA 18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer; Through in silico search the 3'UTR of Ataxia telangiectasia mutated ATM contains a conserved miR-18a binding site; Expression of ATM was down-regulated in CRC tumors p<0.0001 and inversely correlated with miR-18a expression r = -0.4562 p<0.01; This was further confirmed by the down-regulation of ATM protein by miR-18a; As ATM is a key enzyme in DNA damage repair we evaluated the effect of miR-18a on DNA double-strand breaks; miR-18a attenuates cellular repair of DNA double-strand breaks by directly suppressing ATM a key enzyme in DNA damage repair;However the upregulation of miR-18a suppressed the level of ataxia-telangiectasia mutated and attenuated DNA double-strand break repair after irradiation which re-sensitized the cervical cancer cells to radiotherapy by promoting apoptosis;Furthermore we used antisense oligonucleotides against micro RNAs miRNA or miRNA overexpression plasmids to study the role of miR-18a and -106a on ATM expression; Furthermore we identified that ERα activates miR-18a and -106a to downregulate ATM expression; We reveal a novel mechanism involving ERα and miR-18a and -106a regulation of ATM in breast cancer;MicroRNA 18a upregulates autophagy and ataxia telangiectasia mutated gene expression in HCT116 colon cancer cells; Previous studies showed that certain microRNAs including miR-18a potentially regulate ATM in cancer cells; However the mechanisms behind the modulation of ATM by miR-18a remain to be elucidated in colon cancer cells; In the present study we explored the impact of miR-18a on the autophagy process and ATM expression in HCT116 colon cancer cells; Western blotting and luciferase assays were implemented to explore the impact of miR-18a on ATM gene expression in HCT116 cells; Moreover miR-18a overexpression led to the upregulation of ATM expression and suppression of mTORC1 activity; Results of the present study pertaining to the role of miR-18a in regulating autophagy and ATM gene expression in colon cancer cells revealed a novel function for miR-18a in a critical cellular event and on a crucial gene with significant impacts in cancer development progression treatment and in other diseases |
29 | hsa-miR-203a-3p | ATM | 1.98 | 0.03266 | -0.78 | 0.04275 | MirTarget | -0.08 | 0.00835 | 24145123; 27542403 | miR 203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase; In silico analysis identified ataxia telangiectasia mutated ATM a primary mediator of the DNA damage response as a potential target of miR-203; Using TCGA database we identified a significant reverse correlation of miR-203 and ATM expression in CRC tissues; We validated ATM as a bona fide target of miR-203 in CRC cells; Mutation of the putative miR-203 binding site in the 3' untranslated region 3'UTR of the ATM mRNA abolished the inhibitory effect of miR-203 on ATM;MiR 203 inhibits tumor invasion and metastasis in gastric cancer by ATM; Our results showed that miR-203 was significantly downregulated in gastric cancer tissues and cells while ataxia telangiectasia mutated kinase ATM was upregulated in gastric cancer tissues and cells and was directly regulated by miR-203; ATM knockdown phenocopied the effect of miR-203 overexpression |
30 | hsa-miR-455-5p | ATM | -0.23 | 0.54044 | -0.78 | 0.04275 | miRanda | -0.3 | 7.0E-5 | NA | |
31 | hsa-miR-127-3p | BAD | -0.03 | 0.94421 | 0.34 | 0.32274 | miRanda; miRNATAP | -0.18 | 0.00044 | NA | |
32 | hsa-miR-326 | BAD | -0.75 | 0.13947 | 0.34 | 0.32274 | miRanda | -0.25 | 0 | NA | |
33 | hsa-miR-30a-5p | BAX | -0.59 | 0.17531 | -0.04 | 0.88535 | miRNAWalker2 validate | -0.09 | 0.04377 | NA | |
34 | hsa-miR-15b-3p | BCL2 | -0.79 | 0.05785 | -1.63 | 0.00261 | mirMAP | -0.19 | 0.04998 | 25594541; 26915294; 26884837; 18449891 | MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MiR 15b mediates liver cancer cells proliferation through targeting BCL 2; MiR-15b overexpression downregulated BCL2 mRNA and protein expression obviously P < 0.05; On the contrary miR-15b inhibitor transfection markedly reduced miR-15b expression in liver cancer cells P < 0.05 promoted tumor cell proliferation and increased BCL2 mRNA and protein expression; MiR-15b can inhibit HepG2 cell proliferation and down-regulate BCL2 mRNA and protein expression;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2 |
35 | hsa-miR-16-2-3p | BCL2 | -1.03 | 0.00735 | -1.63 | 0.00261 | mirMAP | -0.22 | 0.0345 | NA | |
36 | hsa-miR-17-5p | BCL2 | -0.67 | 0.04231 | -1.63 | 0.00261 | miRNAWalker2 validate; miRTarBase | -0.29 | 0.02016 | 25435430 | Combined overexpression of miR-16 and miR-17 greatly reduced Beclin-1 and Bcl-2 expressions respectively; miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1 whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2 |
37 | hsa-miR-182-5p | BCL2 | 0.19 | 0.7303 | -1.63 | 0.00261 | miRNAWalker2 validate; miRTarBase; mirMAP | -0.4 | 0 | 23936432; 26870290 | Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR 182 and p21; Bcl2 and p21 were identified to be potential target genes of miR-182 in PC3 cells;The expression levels of B-cell lymphoma-2 Bcl-2 and microRNA-182 miR-182 were detected using western blot analysis and quantitative reverse transcription-polymerase chain reaction respectively; Mangiferin treatment was also able to significantly reduce Bcl-2 expression levels and enhance miR-182 expression in PC3 cells; Finally it was observed that mangiferin inhibited proliferation and induced apoptosis in PC3 human prostate cancer cells and this effect was correlated with downregulation of Bcl-2 and upregulation of miR-182 |
38 | hsa-miR-192-5p | BCL2 | 2.1 | 0.00233 | -1.63 | 0.00261 | miRNAWalker2 validate | -0.31 | 0 | 26550150 | MicroRNA 192 regulates chemo resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl 2; In this paper we try to test whether miR-192 regulates chemo-resistance in human carcinoma A549 mice model by targeting Bcl-2; MTT assay real-time RT-PCR western blotting assay were used to investigate miR-192 expression levels cell viability ratio and Bcl-2 protein expression levels; Bcl-2 mRNA and protein expression levels up-regulated in miR-192 inhibitor treated tumor; Bcl-2 is a key regulator for miR-192 related chemotherapy resistance; In this study we demonstrate that miR-192 regulates chemoresistance for gemcitabine and cisplatin combined chemotherapy in human adenocarcinoma lung cancer A549 cells and Bcl-2 is the target of miR-192 |
39 | hsa-miR-196b-5p | BCL2 | 1.33 | 0.19807 | -1.63 | 0.00261 | miRNAWalker2 validate | -0.13 | 0.00097 | NA | |
40 | hsa-miR-200a-5p | BCL2 | 2.65 | 1.0E-5 | -1.63 | 0.00261 | mirMAP | -0.37 | 0 | NA | |
41 | hsa-miR-200b-3p | BCL2 | 1.84 | 0.00297 | -1.63 | 0.00261 | miRNAWalker2 validate; miRTarBase; TargetScan; mirMAP | -0.46 | 0 | NA | |
42 | hsa-miR-200b-5p | BCL2 | 0.86 | 0.18327 | -1.63 | 0.00261 | mirMAP | -0.46 | 0 | NA | |
43 | hsa-miR-200c-3p | BCL2 | 1.56 | 0.01265 | -1.63 | 0.00261 | miRNAWalker2 validate; miRTarBase; mirMAP | -0.4 | 0 | NA | |
44 | hsa-miR-20a-5p | BCL2 | -0.39 | 0.26959 | -1.63 | 0.00261 | miRNAWalker2 validate; miRTarBase | -0.29 | 0.01076 | NA | |
45 | hsa-miR-215-5p | BCL2 | 3.07 | 0.00158 | -1.63 | 0.00261 | miRNAWalker2 validate | -0.11 | 0.00607 | NA | |
46 | hsa-miR-224-5p | BCL2 | -0.27 | 0.69436 | -1.63 | 0.00261 | mirMAP | -0.19 | 0.00121 | 24796455 | In addition the expressions of Bcl2 mRNA and protein were 1.05 ± 0.04 and 0.21 ± 0.03 in the miR-224 ASO group significantly lower than that in the control group 4.87 ± 0.96 and 0.88 ± 0.09 P < 0.01 |
47 | hsa-miR-29a-5p | BCL2 | -0.6 | 0.06643 | -1.63 | 0.00261 | mirMAP | -0.25 | 0.04539 | 20041405 | Subsequent investigation characterized two antiapoptotic molecules Bcl-2 and Mcl-1 as direct targets of miR-29; Furthermore silencing of Bcl-2 and Mcl-1 phenocopied the proapoptotic effect of miR-29 whereas overexpression of these proteins attenuated the effect of miR-29 |
48 | hsa-miR-29b-3p | BCL2 | -0.39 | 0.34358 | -1.63 | 0.00261 | miRNAWalker2 validate; miRTarBase | -0.21 | 0.02912 | 20041405 | Subsequent investigation characterized two antiapoptotic molecules Bcl-2 and Mcl-1 as direct targets of miR-29; Furthermore silencing of Bcl-2 and Mcl-1 phenocopied the proapoptotic effect of miR-29 whereas overexpression of these proteins attenuated the effect of miR-29 |
49 | hsa-miR-3065-5p | BCL2 | 0.74 | 0.29684 | -1.63 | 0.00261 | mirMAP | -0.12 | 0.0323 | NA | |
50 | hsa-miR-33a-5p | BCL2 | -0.99 | 0.06458 | -1.63 | 0.00261 | mirMAP | -0.24 | 0.0011 | NA | |
51 | hsa-miR-33b-5p | BCL2 | 0.62 | 0.3293 | -1.63 | 0.00261 | miRTarBase; mirMAP | -0.19 | 0.00291 | NA | |
52 | hsa-miR-34a-5p | BCL2 | -0.24 | 0.41696 | -1.63 | 0.00261 | miRNAWalker2 validate; miRTarBase | -0.4 | 0.0035 | 19714243; 24565525; 23155233; 24444609; 20687223; 22623155; 24988056; 18803879; 25053345; 20433755; 21399894; 22964582; 23862748 | Among the target proteins regulated by miR-34 are Notch pathway proteins and Bcl-2 suggesting the possibility of a role for miR-34 in the maintenance and survival of cancer stem cells; Our data support the view that miR-34 may be involved in pancreatic cancer stem cell self-renewal potentially via the direct modulation of downstream targets Bcl-2 and Notch implying that miR-34 may play an important role in pancreatic cancer stem cell self-renewal and/or cell fate determination;In vitro and in vivo experiments showed that miR-34a and DOX can be efficiently encapsulated into HA-CS NPs and delivered into tumor cells or tumor tissues and enhance anti-tumor effects of DOX by suppressing the expression of non-pump resistance and anti-apoptosis proto-oncogene Bcl-2;The miR-34a expression levels in cells after irradiation at 30 and 60 Gy were 0.17- and 18.7-times the BCL2 and caspase-9 expression levels respectively;Functional analyses further indicate that restoration of miR-34a inhibits B cell lymphoma-2 Bcl-2 protein expression to withdraw the survival advantage of these resistant NSCLC cells;Thus in PC3PR cells reduced expression of miR-34a confers paclitaxel resistance via up-regulating SIRT1 and Bcl2 expression; MiR-34a and its downstream targets SIRT1 and Bcl2 play important roles in the development of paclitaxel resistance all of which can be useful biomarkers and promising therapeutic targets for the drug resistance in hormone-refractory prostate cancer;MiR 34a inhibits proliferation and migration of breast cancer through down regulation of Bcl 2 and SIRT1; In this study we aimed to determine the effect of miR-34a on the growth of breast cancer and to investigate whether its effect is achieved by targeting Bcl-2 and SIRT1; Bcl-2 and SIRT1 as the targets of miR-34a were found to be in reverse correlation with ectopic expression of miR-34a;Target analysis indicated that micro RNA miR-34a directly regulates Bcl-2 and miR-34a overexpression decreased Bcl-2 protein level in gastric cancer cells; We also found that luteolin upregulates miR-34a expression and downregulates Bcl-2 expression; Based on these results we can draw the conclusion that luteolin partly decreases Bcl-2 expression through upregulating miR-34a expression;miR-34 targets Notch HMGA2 and Bcl-2 genes involved in the self-renewal and survival of cancer stem cells; Human gastric cancer cells were transfected with miR-34 mimics or infected with the lentiviral miR-34-MIF expression system and validated by miR-34 reporter assay using Bcl-2 3'UTR reporter; Human gastric cancer Kato III cells with miR-34 restoration reduced the expression of target genes Bcl-2 Notch and HMGA2; Bcl-2 3'UTR reporter assay showed that the transfected miR-34s were functional and confirmed that Bcl-2 is a direct target of miR-34; The mechanism of miR-34-mediated suppression of self-renewal appears to be related to the direct modulation of downstream targets Bcl-2 Notch and HMGA2 indicating that miR-34 may be involved in gastric cancer stem cell self-renewal/differentiation decision-making;Manipulating miR-34a in prostate cancer cells confirms that this miRNA regulates BCL-2 and may in part regulate response to docetaxel;For instance miR-34a up-regulation corresponded with a down-regulation of BCL2 protein; Treating Par-4-overexpressing HT29 cells with a miR-34a antagomir functionally reversed both BCL2 down-regulation and apoptosis by 5-FU;Quantitative PCR and western analysis confirmed decreased expression of two genes BCL-2 and CCND1 in docetaxel-resistant cells which are both targeted by miR-34a;Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2;MicroRNA 34a targets Bcl 2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment; HCC tissues with lower miR-34a expression displayed higher expression of Bcl-2 protein than those with high expression of miR-34a; therefore an inverse correlation is evident between the miR-34a level and Bcl-2 expression; Bioinformatics and luciferase reporter assays revealed that miR-34a binds the 3'-UTR of the Bcl-2 mRNA and represses its translation; Western blotting analysis and qRT-PCR confirmed that Bcl-2 is inhibited by miR-34a overexpression; Functional analyses indicated that the restoration of miR-34a reduced cell viability promoted cell apoptosis and potentiated sorafenib-induced apoptosis and toxicity in HCC cell lines by inhibiting Bcl-2 expression |
53 | hsa-miR-429 | BCL2 | 1.86 | 0.00726 | -1.63 | 0.00261 | miRNAWalker2 validate; miRTarBase; PITA; mirMAP | -0.4 | 0 | 23999873; 26513239; 26511969 | MiR 429 up regulation induces apoptosis and suppresses invasion by targeting Bcl 2 and SP 1 in esophageal carcinoma; Subsequent Western blotting and luciferase reporter assays showed that miR-429 can bind to putative binding sites within the Bcl-2 and SP1 mRNA 3' untranslated regions UTRs to reduce their expression; Up-regulation of miR-429 inhibits invasion and promotes apoptosis in EC cells by targeting Bcl-2 and SP1; Our findings suggest that Bcl-2 and SP1 may serve as major targets of miR-429;MiR 429 Induces Gastric Carcinoma Cell Apoptosis Through Bcl 2; Here we studied the levels of miR-429 and anti-apoptotic protein Bcl-2 in GC specimens; We performed bioinformatics analyses and used luciferase-reporter assay to analyze the relationship between miR-429 and Bcl-2 in GC cells; MiR-429 levels were significantly decreased and Bcl-2 levels were significantly increased in GC specimens compared to the paired adjacent non-tumor gastric tissue; Moreover the levels of miR-429 and Bcl-2 inversely correlated in GC specimens; Bioinformatics analyses showed that miR-429 targeted the 3'-UTR of Bcl-2 mRNA to inhibit its translation which was confirmed by luciferase-reporter assay;MiR 429 induces apoptosis of glioblastoma cell through Bcl 2; Here we analyzed the levels of miR-429 and anti-apoptotic protein Bcl-2 in GBM specimens; We combined bioinformatics analyses and luciferase reporter assay to determine the relationship between miR-429 and Bcl-2 in GBM cells; We found that miR-429 levels were significantly decreased and Bcl-2 levels were significantly increased in GBM specimens compared to the paired adjacent non-tumor brain tissue; Moreover the levels of miR-429 and Bcl-2 inversely correlated; MiR-429 targeted the 3'-UTR of Bcl-2 mRNA to inhibit its translation |
54 | hsa-miR-455-5p | BCL2 | -0.23 | 0.54044 | -1.63 | 0.00261 | mirMAP | -0.37 | 0.0005 | NA | |
55 | hsa-miR-577 | BCL2 | 0.81 | 0.31426 | -1.63 | 0.00261 | PITA | -0.11 | 0.03266 | NA | |
56 | hsa-miR-582-5p | BCL2 | -0.24 | 0.6387 | -1.63 | 0.00261 | PITA | -0.16 | 0.04038 | NA | |
57 | hsa-miR-96-5p | BCL2 | -0.14 | 0.83402 | -1.63 | 0.00261 | miRNAWalker2 validate; TargetScan | -0.43 | 0 | NA | |
58 | hsa-let-7g-3p | BCL2L1 | -0.84 | 0.01923 | 0.86 | 0.00506 | miRNATAP | -0.18 | 0.0056 | 20347499 | Over-expression of let-7c or let-7g led to a clear decrease of Bcl-xL expression in Huh7 and HepG2 cell lines; Reporter assays revealed direct post-transcriptional regulation involving let-7c or let-7g and the 3'-untranslated region of bcl-xl mRNA |
59 | hsa-miR-140-5p | BCL2L1 | -1.2 | 4.0E-5 | 0.86 | 0.00506 | PITA; miRanda; miRNATAP | -0.31 | 6.0E-5 | NA | |
60 | hsa-miR-185-3p | BCL2L1 | -0.81 | 0.0588 | 0.86 | 0.00506 | mirMAP; miRNATAP | -0.13 | 0.0178 | NA | |
61 | hsa-miR-30b-3p | BCL2L1 | -0.57 | 0.2349 | 0.86 | 0.00506 | MirTarget | -0.14 | 0.00253 | NA | |
62 | hsa-miR-326 | BCL2L1 | -0.75 | 0.13947 | 0.86 | 0.00506 | PITA; miRanda; mirMAP; miRNATAP | -0.11 | 0.01797 | NA | |
63 | hsa-miR-330-5p | BCL2L1 | 0.65 | 0.08635 | 0.86 | 0.00506 | PITA; miRanda; miRNATAP | -0.13 | 0.03818 | NA | |
64 | hsa-miR-342-3p | BCL2L1 | -1.51 | 0.00036 | 0.86 | 0.00506 | PITA; miRanda; miRNATAP | -0.19 | 0.00038 | NA | |
65 | hsa-miR-342-5p | BCL2L1 | -1.68 | 7.0E-5 | 0.86 | 0.00506 | miRNATAP | -0.17 | 0.00106 | NA | |
66 | hsa-miR-377-3p | BCL2L1 | -1.31 | 0.02275 | 0.86 | 0.00506 | MirTarget | -0.11 | 0.00391 | NA | |
67 | hsa-miR-421 | BCL2L1 | -0.18 | 0.69194 | 0.86 | 0.00506 | miRanda | -0.17 | 0.00128 | NA | |
68 | hsa-miR-484 | BCL2L1 | -1.18 | 5.0E-5 | 0.86 | 0.00506 | miRNAWalker2 validate | -0.19 | 0.01279 | NA | |
69 | hsa-miR-664a-5p | BCL2L1 | -0.92 | 0.03703 | 0.86 | 0.00506 | mirMAP | -0.19 | 0.00013 | NA | |
70 | hsa-miR-137 | BID | -0.08 | 0.93052 | 0.09 | 0.77131 | miRanda | -0.06 | 0.02093 | NA | |
71 | hsa-miR-370-3p | BID | -0.69 | 0.22721 | 0.09 | 0.77131 | MirTarget | -0.13 | 0.00091 | NA | |
72 | hsa-miR-543 | BID | -1.03 | 0.07135 | 0.09 | 0.77131 | miRanda | -0.1 | 0.00802 | NA | |
73 | hsa-miR-29b-3p | BIRC2 | -0.39 | 0.34358 | -0.1 | 0.59262 | MirTarget | -0.11 | 0.00043 | NA | |
74 | hsa-miR-29c-3p | BIRC2 | -0.13 | 0.74361 | -0.1 | 0.59262 | MirTarget | -0.09 | 0.00625 | NA | |
75 | hsa-miR-421 | BIRC2 | -0.18 | 0.69194 | -0.1 | 0.59262 | miRanda | -0.06 | 0.03743 | NA | |
76 | hsa-miR-500a-5p | BIRC2 | -1.1 | 0.01791 | -0.1 | 0.59262 | MirTarget | -0.08 | 0.00598 | NA | |
77 | hsa-miR-129-5p | BIRC3 | 1.01 | 0.36712 | -0.62 | 0.37166 | miRanda | -0.21 | 0 | NA | |
78 | hsa-miR-338-5p | BIRC3 | 0.34 | 0.53294 | -0.62 | 0.37166 | mirMAP | -0.21 | 0.02361 | NA | |
79 | hsa-miR-369-3p | BIRC3 | -0.83 | 0.17364 | -0.62 | 0.37166 | MirTarget; miRNATAP | -0.41 | 0 | NA | |
80 | hsa-miR-375 | BIRC3 | 2.46 | 0.01711 | -0.62 | 0.37166 | miRNAWalker2 validate | -0.28 | 0 | 23726271 | Taken together these data suggest that miR-375 sensitizes TNF-α-induced apoptosis and the reduction in the expression of the apoptosis inhibitory proteins cFLIP-L and cIAP2 plays an important role in this sensitization |
81 | hsa-miR-496 | BIRC3 | -0.26 | 0.66888 | -0.62 | 0.37166 | mirMAP | -0.31 | 0.00016 | NA | |
82 | hsa-miR-577 | BIRC3 | 0.81 | 0.31426 | -0.62 | 0.37166 | MirTarget | -0.15 | 0.01912 | NA | |
83 | hsa-miR-664a-3p | BIRC3 | -0.55 | 0.06802 | -0.62 | 0.37166 | mirMAP | -0.71 | 3.0E-5 | NA | |
84 | hsa-miR-98-5p | BIRC3 | -0.22 | 0.42277 | -0.62 | 0.37166 | miRNAWalker2 validate | -1 | 0 | NA | |
85 | hsa-miR-140-5p | CAPN1 | -1.2 | 4.0E-5 | 0.32 | 0.26978 | miRanda; miRNATAP | -0.24 | 0.0007 | NA | |
86 | hsa-miR-491-5p | CAPN1 | -0.79 | 0.12393 | 0.32 | 0.26978 | miRanda | -0.13 | 0.00224 | NA | |
87 | hsa-miR-101-3p | CAPN2 | -0.27 | 0.36572 | 0.82 | 0.00458 | miRNAWalker2 validate; MirTarget | -0.31 | 2.0E-5 | NA | |
88 | hsa-miR-129-5p | CAPN2 | 1.01 | 0.36712 | 0.82 | 0.00458 | miRanda | -0.08 | 6.0E-5 | NA | |
89 | hsa-miR-137 | CAPN2 | -0.08 | 0.93052 | 0.82 | 0.00458 | MirTarget; PITA; miRanda | -0.08 | 0.00069 | NA | |
90 | hsa-miR-1468-5p | CAPN2 | -0.37 | 0.52678 | 0.82 | 0.00458 | MirTarget | -0.18 | 0 | NA | |
91 | hsa-miR-421 | CAPN2 | -0.18 | 0.69194 | 0.82 | 0.00458 | miRanda | -0.17 | 0.00037 | NA | |
92 | hsa-miR-590-3p | CAPN2 | -0.92 | 0.03456 | 0.82 | 0.00458 | miRanda | -0.15 | 0.00183 | NA | |
93 | hsa-miR-590-5p | CAPN2 | -0.98 | 0.00534 | 0.82 | 0.00458 | miRanda | -0.19 | 0.00163 | NA | |
94 | hsa-miR-7-5p | CAPN2 | 0.82 | 0.51059 | 0.82 | 0.00458 | miRNAWalker2 validate | -0.1 | 0 | NA | |
95 | hsa-miR-125a-5p | CASP10 | -0.31 | 0.3708 | -0.18 | 0.62889 | mirMAP | -0.33 | 2.0E-5 | NA | |
96 | hsa-miR-129-2-3p | CASP10 | 0.5 | 0.64185 | -0.18 | 0.62889 | mirMAP | -0.13 | 0 | NA | |
97 | hsa-miR-129-5p | CASP10 | 1.01 | 0.36712 | -0.18 | 0.62889 | mirMAP | -0.13 | 0 | NA | |
98 | hsa-miR-144-5p | CASP10 | -2.21 | 0.00517 | -0.18 | 0.62889 | mirMAP | -0.08 | 0.02097 | NA | |
99 | hsa-miR-148b-5p | CASP10 | -0.01 | 0.99005 | -0.18 | 0.62889 | mirMAP | -0.2 | 3.0E-5 | NA | |
100 | hsa-miR-181c-5p | CASP10 | 0.39 | 0.3054 | -0.18 | 0.62889 | mirMAP | -0.19 | 0.00574 | NA | |
101 | hsa-miR-30b-3p | CASP10 | -0.57 | 0.2349 | -0.18 | 0.62889 | MirTarget | -0.16 | 0.00438 | NA | |
102 | hsa-miR-338-3p | CASP10 | 0.51 | 0.34448 | -0.18 | 0.62889 | miRanda | -0.14 | 0.00315 | NA | |
103 | hsa-miR-338-5p | CASP10 | 0.34 | 0.53294 | -0.18 | 0.62889 | mirMAP | -0.12 | 0.0125 | NA | |
104 | hsa-miR-361-5p | CASP10 | -0.3 | 0.18864 | -0.18 | 0.62889 | miRanda | -0.57 | 0 | NA | |
105 | hsa-miR-3613-3p | CASP10 | -0.97 | 0.05661 | -0.18 | 0.62889 | MirTarget | -0.12 | 0.02434 | NA | |
106 | hsa-miR-421 | CASP10 | -0.18 | 0.69194 | -0.18 | 0.62889 | mirMAP | -0.32 | 0 | NA | |
107 | hsa-miR-592 | CASP10 | 1.03 | 0.22889 | -0.18 | 0.62889 | miRNATAP | -0.12 | 0.00077 | NA | |
108 | hsa-miR-744-3p | CASP10 | -0.55 | 0.24228 | -0.18 | 0.62889 | mirMAP | -0.34 | 0 | NA | |
109 | hsa-miR-129-5p | CASP3 | 1.01 | 0.36712 | -0.01 | 0.97941 | mirMAP | -0.06 | 2.0E-5 | 23744359 | The intrinsic apoptotic pathway triggered by miR-129 was activated by cleavage of caspase-9 and caspase-3 |
110 | hsa-miR-137 | CASP3 | -0.08 | 0.93052 | -0.01 | 0.97941 | MirTarget; miRanda | -0.06 | 0.00242 | 27429846 | Oncogenic miR 137 contributes to cisplatin resistance via repressing CASP3 in lung adenocarcinoma; Through computational prediction and microarray we identified caspase-3 CASP3 as a potential target of miR-137; Luciferase reporter and site-directed mutagenesis assays demonstrated that miR-137 downregulates CASP3 through binding to its 3'-UTR; Moreover the endogenous CASP3 can be modulated by overexpressing or silencing miR-137 in lung adenocarcinoma cell lines regardless of EGFR status; Suppression of CASP3 by miR-137 provides cancer cells with anti-apoptotic ability leading to cisplatin resistance; Immunohistochemistry results revealed an inverse correlation between miR-137 and CASP3 expressions in lung adenocarcinoma patients |
111 | hsa-miR-139-5p | CASP3 | -1.64 | 0.00654 | -0.01 | 0.97941 | miRanda | -0.08 | 0.00324 | NA | |
112 | hsa-miR-30a-5p | CASP3 | -0.59 | 0.17531 | -0.01 | 0.97941 | miRNATAP | -0.08 | 0.03017 | NA | |
113 | hsa-miR-30c-5p | CASP3 | -0.88 | 0.00777 | -0.01 | 0.97941 | miRNATAP | -0.12 | 0.01479 | NA | |
114 | hsa-miR-98-5p | CASP3 | -0.22 | 0.42277 | -0.01 | 0.97941 | MirTarget | -0.21 | 0.0004 | NA | |
115 | hsa-miR-125a-5p | CASP6 | -0.31 | 0.3708 | 0.22 | 0.45531 | miRanda | -0.34 | 0 | NA | |
116 | hsa-miR-129-5p | CASP6 | 1.01 | 0.36712 | 0.22 | 0.45531 | MirTarget; miRanda | -0.11 | 0 | NA | |
117 | hsa-miR-369-3p | CASP6 | -0.83 | 0.17364 | 0.22 | 0.45531 | MirTarget | -0.15 | 2.0E-5 | NA | |
118 | hsa-miR-129-5p | CASP7 | 1.01 | 0.36712 | 0.21 | 0.50664 | miRanda | -0.07 | 0.00076 | NA | |
119 | hsa-miR-132-3p | CASP7 | -0.19 | 0.63856 | 0.21 | 0.50664 | miRNAWalker2 validate; MirTarget | -0.29 | 0 | NA | |
120 | hsa-miR-137 | CASP7 | -0.08 | 0.93052 | 0.21 | 0.50664 | miRanda | -0.12 | 1.0E-5 | NA | |
121 | hsa-miR-212-3p | CASP7 | -0.37 | 0.45016 | 0.21 | 0.50664 | MirTarget | -0.18 | 8.0E-5 | NA | |
122 | hsa-miR-3065-3p | CASP7 | 0.92 | 0.14952 | 0.21 | 0.50664 | MirTarget | -0.15 | 2.0E-5 | NA | |
123 | hsa-miR-361-5p | CASP7 | -0.3 | 0.18864 | 0.21 | 0.50664 | PITA; miRanda | -0.37 | 0.00041 | NA | |
124 | hsa-miR-543 | CASP7 | -1.03 | 0.07135 | 0.21 | 0.50664 | miRanda | -0.16 | 6.0E-5 | NA | |
125 | hsa-miR-664a-3p | CASP7 | -0.55 | 0.06802 | 0.21 | 0.50664 | MirTarget | -0.19 | 0.01551 | NA | |
126 | hsa-miR-107 | CASP8 | 0.04 | 0.89912 | -0.22 | 0.5858 | miRanda | -0.22 | 0.03943 | NA | |
127 | hsa-miR-129-5p | CASP8 | 1.01 | 0.36712 | -0.22 | 0.5858 | miRanda | -0.17 | 0 | NA | |
128 | hsa-miR-137 | CASP8 | -0.08 | 0.93052 | -0.22 | 0.5858 | miRanda | -0.08 | 0.016 | NA | |
129 | hsa-miR-296-3p | CASP8 | -0.4 | 0.5034 | -0.22 | 0.5858 | miRanda | -0.15 | 0.00785 | NA | |
130 | hsa-miR-3607-3p | CASP8 | -0.1 | 0.81827 | -0.22 | 0.5858 | mirMAP | -0.16 | 0.02174 | NA | |
131 | hsa-miR-3613-3p | CASP8 | -0.97 | 0.05661 | -0.22 | 0.5858 | mirMAP | -0.12 | 0.04936 | NA | |
132 | hsa-miR-376a-3p | CASP8 | -0.6 | 0.34279 | -0.22 | 0.5858 | TargetScan | -0.23 | 0 | NA | |
133 | hsa-miR-421 | CASP8 | -0.18 | 0.69194 | -0.22 | 0.5858 | miRanda | -0.31 | 0 | NA | |
134 | hsa-miR-543 | CASP8 | -1.03 | 0.07135 | -0.22 | 0.5858 | miRanda | -0.23 | 1.0E-5 | NA | |
135 | hsa-miR-125b-2-3p | CASP9 | 0.59 | 0.24105 | -0.26 | 0.21002 | mirMAP | -0.08 | 0.01092 | NA | |
136 | hsa-miR-103a-2-5p | CFLAR | -2.06 | 0.00116 | -0.19 | 0.52443 | mirMAP | -0.08 | 0.01923 | NA | |
137 | hsa-miR-125a-5p | CFLAR | -0.31 | 0.3708 | -0.19 | 0.52443 | miRanda | -0.23 | 0.00048 | NA | |
138 | hsa-miR-301a-3p | CFLAR | -0.76 | 0.09613 | -0.19 | 0.52443 | mirMAP | -0.2 | 2.0E-5 | NA | |
139 | hsa-miR-30b-3p | CFLAR | -0.57 | 0.2349 | -0.19 | 0.52443 | mirMAP | -0.12 | 0.00905 | NA | |
140 | hsa-miR-338-3p | CFLAR | 0.51 | 0.34448 | -0.19 | 0.52443 | miRanda; mirMAP | -0.14 | 0.00067 | NA | |
141 | hsa-miR-3613-3p | CFLAR | -0.97 | 0.05661 | -0.19 | 0.52443 | mirMAP | -0.09 | 0.0449 | NA | |
142 | hsa-miR-377-3p | CFLAR | -1.31 | 0.02275 | -0.19 | 0.52443 | mirMAP | -0.17 | 0 | NA | |
143 | hsa-miR-421 | CFLAR | -0.18 | 0.69194 | -0.19 | 0.52443 | miRanda | -0.13 | 0.00909 | NA | |
144 | hsa-miR-454-3p | CFLAR | -1.27 | 0.00176 | -0.19 | 0.52443 | mirMAP | -0.11 | 0.04499 | NA | |
145 | hsa-miR-455-5p | CFLAR | -0.23 | 0.54044 | -0.19 | 0.52443 | miRanda | -0.19 | 0.00111 | NA | |
146 | hsa-miR-543 | CFLAR | -1.03 | 0.07135 | -0.19 | 0.52443 | miRanda | -0.15 | 6.0E-5 | NA | |
147 | hsa-miR-550a-5p | CFLAR | 0.44 | 0.37018 | -0.19 | 0.52443 | mirMAP | -0.11 | 0.01176 | NA | |
148 | hsa-miR-660-5p | CFLAR | -0.2 | 0.55612 | -0.19 | 0.52443 | mirMAP | -0.16 | 0.01845 | NA | |
149 | hsa-miR-7-5p | CFLAR | 0.82 | 0.51059 | -0.19 | 0.52443 | miRNAWalker2 validate | -0.11 | 0 | NA | |
150 | hsa-miR-130a-5p | CHUK | -1.25 | 0.01164 | 0.14 | 0.4695 | MirTarget; miRNATAP | -0.08 | 0.00626 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 24 | 99 | 3.326e-38 | 1.548e-34 |
2 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 53 | 1929 | 1.52e-37 | 3.535e-34 |
3 | INTRACELLULAR SIGNAL TRANSDUCTION | 49 | 1572 | 1.877e-36 | 2.319e-33 |
4 | REGULATION OF CELL DEATH | 48 | 1472 | 1.994e-36 | 2.319e-33 |
5 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 18 | 39 | 1.055e-34 | 9.815e-32 |
6 | APOPTOTIC SIGNALING PATHWAY | 29 | 289 | 1.825e-34 | 1.415e-31 |
7 | CELL DEATH | 41 | 1001 | 5.008e-34 | 3.329e-31 |
8 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 48 | 1848 | 7.665e-32 | 4.458e-29 |
9 | POSITIVE REGULATION OF CELL COMMUNICATION | 45 | 1532 | 1.175e-31 | 6.076e-29 |
10 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 25 | 213 | 2.54e-31 | 1.182e-28 |
11 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 44 | 1492 | 7.167e-31 | 3.032e-28 |
12 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 37 | 876 | 9.652e-31 | 3.742e-28 |
13 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 20 | 95 | 1.946e-30 | 6.964e-28 |
14 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 45 | 1656 | 3.387e-30 | 1.126e-27 |
15 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 42 | 1381 | 9.993e-30 | 2.949e-27 |
16 | POSITIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 23 | 179 | 1.014e-29 | 2.949e-27 |
17 | NEGATIVE REGULATION OF CELL DEATH | 36 | 872 | 1.823e-29 | 4.991e-27 |
18 | ZYMOGEN ACTIVATION | 20 | 112 | 7.098e-29 | 1.835e-26 |
19 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 45 | 1791 | 9.785e-29 | 2.396e-26 |
20 | RESPONSE TO CYTOKINE | 33 | 714 | 2.4e-28 | 5.583e-26 |
21 | IMMUNE SYSTEM PROCESS | 46 | 1984 | 5.176e-28 | 1.147e-25 |
22 | REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 23 | 233 | 5.438e-27 | 1.15e-24 |
23 | POSITIVE REGULATION OF PEPTIDASE ACTIVITY | 20 | 154 | 6.218e-26 | 1.228e-23 |
24 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 11 | 13 | 6.335e-26 | 1.228e-23 |
25 | POSITIVE REGULATION OF CELL DEATH | 29 | 605 | 3.946e-25 | 7.344e-23 |
26 | REGULATION OF PEPTIDASE ACTIVITY | 25 | 392 | 1.376e-24 | 2.463e-22 |
27 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 39 | 1518 | 1.541e-24 | 2.655e-22 |
28 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 17 | 98 | 2.303e-24 | 3.827e-22 |
29 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 19 | 153 | 2.918e-24 | 4.681e-22 |
30 | PROTEIN MATURATION | 22 | 265 | 4.001e-24 | 6.206e-22 |
31 | POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 11 | 17 | 9.936e-24 | 1.491e-21 |
32 | REGULATION OF IMMUNE SYSTEM PROCESS | 37 | 1403 | 1.753e-23 | 2.549e-21 |
33 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 23 | 363 | 1.594e-22 | 2.248e-20 |
34 | CELLULAR RESPONSE TO CYTOKINE STIMULUS | 27 | 606 | 1.747e-22 | 2.391e-20 |
35 | ACTIVATION OF IMMUNE RESPONSE | 24 | 427 | 2.783e-22 | 3.699e-20 |
36 | REGULATION OF IMMUNE RESPONSE | 30 | 858 | 4.458e-22 | 5.761e-20 |
37 | POSITIVE REGULATION OF IMMUNE RESPONSE | 26 | 563 | 5.152e-22 | 6.479e-20 |
38 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 11 | 22 | 5.582e-22 | 6.835e-20 |
39 | REGULATION OF PROTEOLYSIS | 28 | 711 | 6.634e-22 | 7.915e-20 |
40 | CYTOKINE MEDIATED SIGNALING PATHWAY | 24 | 452 | 1.064e-21 | 1.238e-19 |
41 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 18 | 171 | 1.149e-21 | 1.304e-19 |
42 | RESPONSE TO NITROGEN COMPOUND | 29 | 859 | 7.096e-21 | 7.862e-19 |
43 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 29 | 867 | 9.159e-21 | 9.911e-19 |
44 | RESPONSE TO TUMOR NECROSIS FACTOR | 19 | 233 | 1.054e-20 | 1.114e-18 |
45 | NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 18 | 200 | 2.048e-20 | 2.118e-18 |
46 | REGULATION OF TRANSFERASE ACTIVITY | 29 | 946 | 9.989e-20 | 9.683e-18 |
47 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 31 | 1135 | 9.98e-20 | 9.683e-18 |
48 | POSITIVE REGULATION OF PROTEOLYSIS | 21 | 363 | 9.678e-20 | 9.683e-18 |
49 | REGULATION OF KINASE ACTIVITY | 27 | 776 | 1.06e-19 | 1.007e-17 |
50 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 11 | 34 | 2.187e-19 | 2.035e-17 |
51 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 35 | 1618 | 2.936e-19 | 2.679e-17 |
52 | I KAPPAB KINASE NF KAPPAB SIGNALING | 13 | 70 | 3.224e-19 | 2.885e-17 |
53 | ACTIVATION OF INNATE IMMUNE RESPONSE | 17 | 204 | 9.825e-19 | 8.626e-17 |
54 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 29 | 1036 | 1.179e-18 | 9.973e-17 |
55 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 29 | 1036 | 1.179e-18 | 9.973e-17 |
56 | REGULATION OF RESPONSE TO STRESS | 33 | 1468 | 1.554e-18 | 1.291e-16 |
57 | POSITIVE REGULATION OF KINASE ACTIVITY | 22 | 482 | 1.808e-18 | 1.476e-16 |
58 | POSITIVE REGULATION OF DEFENSE RESPONSE | 20 | 364 | 2.275e-18 | 1.825e-16 |
59 | PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 14 | 109 | 2.992e-18 | 2.36e-16 |
60 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 26 | 799 | 3.136e-18 | 2.432e-16 |
61 | REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 15 | 144 | 4.363e-18 | 3.328e-16 |
62 | RESPONSE TO MOLECULE OF BACTERIAL ORIGIN | 19 | 321 | 4.54e-18 | 3.407e-16 |
63 | TOLL LIKE RECEPTOR SIGNALING PATHWAY | 13 | 85 | 4.809e-18 | 3.552e-16 |
64 | TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 14 | 118 | 9.494e-18 | 6.902e-16 |
65 | RESPONSE TO ABIOTIC STIMULUS | 28 | 1024 | 1.036e-17 | 7.416e-16 |
66 | REGULATION OF PROTEIN MODIFICATION PROCESS | 34 | 1710 | 1.646e-17 | 1.161e-15 |
67 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 17 | 246 | 2.382e-17 | 1.654e-15 |
68 | REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 11 | 50 | 2.726e-17 | 1.865e-15 |
69 | RESPONSE TO BIOTIC STIMULUS | 26 | 886 | 3.893e-17 | 2.625e-15 |
70 | PROTEOLYSIS | 29 | 1208 | 7.231e-17 | 4.806e-15 |
71 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 17 | 263 | 7.352e-17 | 4.818e-15 |
72 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 21 | 505 | 8.143e-17 | 5.262e-15 |
73 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 11 | 55 | 8.606e-17 | 5.485e-15 |
74 | RESPONSE TO ENDOGENOUS STIMULUS | 31 | 1450 | 1.078e-16 | 6.778e-15 |
75 | PHOSPHORYLATION | 29 | 1228 | 1.118e-16 | 6.935e-15 |
76 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 17 | 279 | 1.981e-16 | 1.213e-14 |
77 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 22 | 616 | 3.155e-16 | 1.907e-14 |
78 | INTRINSIC APOPTOTIC SIGNALING PATHWAY | 14 | 152 | 3.595e-16 | 2.145e-14 |
79 | REGULATION OF INNATE IMMUNE RESPONSE | 18 | 357 | 6.469e-16 | 3.81e-14 |
80 | REGULATION OF HYDROLASE ACTIVITY | 29 | 1327 | 8.637e-16 | 5.023e-14 |
81 | REGULATION OF NEURON DEATH | 16 | 252 | 8.78e-16 | 5.044e-14 |
82 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 34 | 1977 | 1.354e-15 | 7.683e-14 |
83 | POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 13 | 132 | 1.834e-15 | 1.028e-13 |
84 | PROTEIN PHOSPHORYLATION | 25 | 944 | 1.988e-15 | 1.101e-13 |
85 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 17 | 323 | 2.27e-15 | 1.242e-13 |
86 | INFLAMMATORY RESPONSE | 19 | 454 | 2.717e-15 | 1.47e-13 |
87 | SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 9 | 33 | 2.821e-15 | 1.492e-13 |
88 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 9 | 33 | 2.821e-15 | 1.492e-13 |
89 | RESPONSE TO BACTERIUM | 20 | 528 | 2.974e-15 | 1.555e-13 |
90 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 15 | 228 | 4.52e-15 | 2.337e-13 |
91 | NEURON APOPTOTIC PROCESS | 9 | 35 | 5.134e-15 | 2.597e-13 |
92 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 19 | 470 | 5.094e-15 | 2.597e-13 |
93 | RESPONSE TO LIPID | 24 | 888 | 5.376e-15 | 2.69e-13 |
94 | CELLULAR RESPONSE TO MECHANICAL STIMULUS | 11 | 80 | 7.009e-15 | 3.47e-13 |
95 | RESPONSE TO EXTERNAL STIMULUS | 32 | 1821 | 7.661e-15 | 3.746e-13 |
96 | CELLULAR RESPONSE TO STRESS | 30 | 1565 | 7.728e-15 | 3.746e-13 |
97 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 24 | 905 | 8.17e-15 | 3.919e-13 |
98 | REGULATION OF CELL PROLIFERATION | 29 | 1496 | 1.952e-14 | 9.268e-13 |
99 | REGULATION OF DEFENSE RESPONSE | 22 | 759 | 2.321e-14 | 1.091e-12 |
100 | REGULATION OF NECROTIC CELL DEATH | 8 | 26 | 3.522e-14 | 1.639e-12 |
101 | RESPONSE TO HORMONE | 23 | 893 | 6.313e-14 | 2.908e-12 |
102 | NECROTIC CELL DEATH | 8 | 28 | 6.966e-14 | 3.178e-12 |
103 | NEURON DEATH | 9 | 47 | 9.566e-14 | 4.321e-12 |
104 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 10 | 71 | 9.861e-14 | 4.412e-12 |
105 | MYD88 INDEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 8 | 30 | 1.304e-13 | 5.779e-12 |
106 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 12 | 142 | 1.542e-13 | 6.769e-12 |
107 | IMMUNE RESPONSE | 24 | 1100 | 5.716e-13 | 2.486e-11 |
108 | POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 8 | 36 | 6.625e-13 | 2.854e-11 |
109 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 14 | 264 | 7.775e-13 | 3.319e-11 |
110 | POSITIVE REGULATION OF NEURON DEATH | 9 | 67 | 2.831e-12 | 1.197e-10 |
111 | REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 8 | 43 | 3.11e-12 | 1.304e-10 |
112 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 15 | 360 | 3.517e-12 | 1.461e-10 |
113 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 15 | 365 | 4.282e-12 | 1.748e-10 |
114 | REGULATION OF MEMBRANE PERMEABILITY | 9 | 70 | 4.268e-12 | 1.748e-10 |
115 | HOMEOSTATIC PROCESS | 25 | 1337 | 4.95e-12 | 2.003e-10 |
116 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 15 | 370 | 5.2e-12 | 2.086e-10 |
117 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 8 | 46 | 5.547e-12 | 2.206e-10 |
118 | ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 12 | 195 | 6.797e-12 | 2.68e-10 |
119 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 25 | 1360 | 7.184e-12 | 2.809e-10 |
120 | NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR SIGNALING PATHWAY | 7 | 28 | 7.896e-12 | 3.062e-10 |
121 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 21 | 917 | 9.27e-12 | 3.565e-10 |
122 | PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 8 | 49 | 9.503e-12 | 3.624e-10 |
123 | T CELL APOPTOTIC PROCESS | 6 | 15 | 1.017e-11 | 3.846e-10 |
124 | REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 29 | 1.038e-11 | 3.863e-10 |
125 | POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 29 | 1.038e-11 | 3.863e-10 |
126 | FC RECEPTOR SIGNALING PATHWAY | 12 | 206 | 1.296e-11 | 4.787e-10 |
127 | RESPONSE TO MECHANICAL STIMULUS | 12 | 210 | 1.624e-11 | 5.952e-10 |
128 | NIK NF KAPPAB SIGNALING | 9 | 83 | 2.076e-11 | 7.548e-10 |
129 | CELLULAR RESPONSE TO PEPTIDE | 13 | 274 | 2.24e-11 | 8.08e-10 |
130 | NEGATIVE REGULATION OF CELL COMMUNICATION | 23 | 1192 | 2.419e-11 | 8.658e-10 |
131 | EXECUTION PHASE OF APOPTOSIS | 8 | 55 | 2.521e-11 | 8.954e-10 |
132 | CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 7 | 33 | 2.808e-11 | 9.897e-10 |
133 | T CELL HOMEOSTASIS | 7 | 34 | 3.525e-11 | 1.233e-09 |
134 | POSITIVE REGULATION OF GENE EXPRESSION | 27 | 1733 | 3.611e-11 | 1.254e-09 |
135 | LYMPHOCYTE APOPTOTIC PROCESS | 6 | 18 | 3.738e-11 | 1.289e-09 |
136 | DEFENSE RESPONSE | 23 | 1231 | 4.618e-11 | 1.58e-09 |
137 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 16 | 514 | 4.895e-11 | 1.662e-09 |
138 | MITOCHONDRIAL MEMBRANE ORGANIZATION | 9 | 92 | 5.345e-11 | 1.802e-09 |
139 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 21 | 1008 | 5.43e-11 | 1.818e-09 |
140 | NECROPTOTIC PROCESS | 6 | 21 | 1.083e-10 | 3.6e-09 |
141 | REGULATION OF CATABOLIC PROCESS | 18 | 731 | 1.175e-10 | 3.873e-09 |
142 | REGULATION OF NEURON APOPTOTIC PROCESS | 11 | 192 | 1.182e-10 | 3.873e-09 |
143 | CELLULAR RESPONSE TO HORMONE STIMULUS | 16 | 552 | 1.401e-10 | 4.527e-09 |
144 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 16 | 552 | 1.401e-10 | 4.527e-09 |
145 | STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 9 | 103 | 1.495e-10 | 4.797e-09 |
146 | T CELL RECEPTOR SIGNALING PATHWAY | 10 | 146 | 1.518e-10 | 4.838e-09 |
147 | RESPONSE TO WOUNDING | 16 | 563 | 1.871e-10 | 5.923e-09 |
148 | LEUKOCYTE APOPTOTIC PROCESS | 6 | 23 | 2.003e-10 | 6.299e-09 |
149 | RESPONSE TO PEPTIDE | 14 | 404 | 2.283e-10 | 7.13e-09 |
150 | REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 7 | 44 | 2.438e-10 | 7.564e-09 |
151 | CHEMICAL HOMEOSTASIS | 19 | 874 | 2.683e-10 | 8.267e-09 |
152 | REGULATION OF NECROPTOTIC PROCESS | 5 | 11 | 2.744e-10 | 8.401e-09 |
153 | RESPONSE TO AMINO ACID | 9 | 112 | 3.188e-10 | 9.694e-09 |
154 | PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 6 | 25 | 3.494e-10 | 1.056e-08 |
155 | POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS | 7 | 47 | 3.967e-10 | 1.191e-08 |
156 | RESPONSE TO INTERLEUKIN 1 | 9 | 115 | 4.044e-10 | 1.206e-08 |
157 | REGULATION OF MITOCHONDRION ORGANIZATION | 11 | 218 | 4.591e-10 | 1.361e-08 |
158 | RESPONSE TO OXIDATIVE STRESS | 13 | 352 | 4.962e-10 | 1.461e-08 |
159 | PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS | 9 | 120 | 5.926e-10 | 1.734e-08 |
160 | LYMPHOCYTE HOMEOSTASIS | 7 | 50 | 6.245e-10 | 1.816e-08 |
161 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 12 | 289 | 6.521e-10 | 1.885e-08 |
162 | INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY | 5 | 13 | 7.601e-10 | 2.183e-08 |
163 | INOSITOL LIPID MEDIATED SIGNALING | 9 | 124 | 7.947e-10 | 2.269e-08 |
164 | REGULATION OF ORGANELLE ORGANIZATION | 21 | 1178 | 9.407e-10 | 2.669e-08 |
165 | POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 7 | 53 | 9.552e-10 | 2.694e-08 |
166 | CELLULAR RESPONSE TO INTERLEUKIN 1 | 8 | 88 | 1.208e-09 | 3.385e-08 |
167 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 20 | 1079 | 1.334e-09 | 3.717e-08 |
168 | WOUND HEALING | 14 | 470 | 1.626e-09 | 4.502e-08 |
169 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 6 | 32 | 1.752e-09 | 4.795e-08 |
170 | NEGATIVE REGULATION OF SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 6 | 32 | 1.752e-09 | 4.795e-08 |
171 | REGULATION OF MAP KINASE ACTIVITY | 12 | 319 | 2e-09 | 5.441e-08 |
172 | CELL ACTIVATION | 15 | 568 | 2.041e-09 | 5.522e-08 |
173 | RESPONSE TO INORGANIC SUBSTANCE | 14 | 479 | 2.074e-09 | 5.578e-08 |
174 | LEUKOCYTE HOMEOSTASIS | 7 | 60 | 2.345e-09 | 6.27e-08 |
175 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 25 | 1805 | 2.91e-09 | 7.736e-08 |
176 | ACTIVATION OF PROTEIN KINASE A ACTIVITY | 5 | 17 | 3.613e-09 | 9.552e-08 |
177 | PEPTIDYL SERINE MODIFICATION | 9 | 148 | 3.824e-09 | 1.005e-07 |
178 | POSITIVE REGULATION OF TRANSPORT | 18 | 936 | 6e-09 | 1.568e-07 |
179 | REGULATION OF INTRACELLULAR TRANSPORT | 15 | 621 | 6.806e-09 | 1.769e-07 |
180 | REGULATION OF PROTEIN LOCALIZATION | 18 | 950 | 7.56e-09 | 1.954e-07 |
181 | LEUKOCYTE DIFFERENTIATION | 11 | 292 | 9.843e-09 | 2.518e-07 |
182 | REGULATION OF NIK NF KAPPAB SIGNALING | 6 | 42 | 9.85e-09 | 2.518e-07 |
183 | POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION | 9 | 167 | 1.104e-08 | 2.806e-07 |
184 | CELLULAR COMPONENT DISASSEMBLY INVOLVED IN EXECUTION PHASE OF APOPTOSIS | 6 | 43 | 1.141e-08 | 2.886e-07 |
185 | CELLULAR GLUCOSE HOMEOSTASIS | 7 | 75 | 1.153e-08 | 2.9e-07 |
186 | GLUCOSE HOMEOSTASIS | 9 | 170 | 1.289e-08 | 3.208e-07 |
187 | CARBOHYDRATE HOMEOSTASIS | 9 | 170 | 1.289e-08 | 3.208e-07 |
188 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 13 | 465 | 1.414e-08 | 3.499e-07 |
189 | RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 5 | 22 | 1.516e-08 | 3.731e-07 |
190 | REGULATION OF MAPK CASCADE | 15 | 660 | 1.535e-08 | 3.739e-07 |
191 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 8 | 121 | 1.534e-08 | 3.739e-07 |
192 | POSITIVE REGULATION OF MAPK CASCADE | 13 | 470 | 1.604e-08 | 3.888e-07 |
193 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 18 | 1004 | 1.777e-08 | 4.285e-07 |
194 | MITOCHONDRIAL TRANSPORT | 9 | 177 | 1.832e-08 | 4.393e-07 |
195 | RESPONSE TO OXYGEN LEVELS | 11 | 311 | 1.885e-08 | 4.475e-07 |
196 | HEMOSTASIS | 11 | 311 | 1.885e-08 | 4.475e-07 |
197 | RESPONSE TO TOXIC SUBSTANCE | 10 | 241 | 1.959e-08 | 4.626e-07 |
198 | RESPONSE TO UV | 8 | 126 | 2.11e-08 | 4.959e-07 |
199 | RESPONSE TO ACID CHEMICAL | 11 | 319 | 2.446e-08 | 5.663e-07 |
200 | IMMUNE SYSTEM DEVELOPMENT | 14 | 582 | 2.445e-08 | 5.663e-07 |
201 | REGULATION OF EXECUTION PHASE OF APOPTOSIS | 5 | 24 | 2.432e-08 | 5.663e-07 |
202 | RESPONSE TO VIRUS | 10 | 247 | 2.472e-08 | 5.695e-07 |
203 | MITOCHONDRION ORGANIZATION | 14 | 594 | 3.154e-08 | 7.228e-07 |
204 | POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 6 | 51 | 3.294e-08 | 7.476e-07 |
205 | RESPONSE TO NICOTINE | 6 | 51 | 3.294e-08 | 7.476e-07 |
206 | LEUKOCYTE CELL CELL ADHESION | 10 | 255 | 3.341e-08 | 7.547e-07 |
207 | NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 7 | 88 | 3.55e-08 | 7.941e-07 |
208 | RESPONSE TO REACTIVE OXYGEN SPECIES | 9 | 191 | 3.542e-08 | 7.941e-07 |
209 | POSITIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY | 6 | 52 | 3.713e-08 | 8.266e-07 |
210 | PHOSPHATIDYLINOSITOL METABOLIC PROCESS | 9 | 193 | 3.875e-08 | 8.586e-07 |
211 | RESPONSE TO ALKALOID | 8 | 137 | 4.066e-08 | 8.966e-07 |
212 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 16 | 829 | 4.645e-08 | 1.02e-06 |
213 | CELLULAR RESPONSE TO DNA DAMAGE STIMULUS | 15 | 720 | 4.84e-08 | 1.057e-06 |
214 | LYMPHOCYTE ACTIVATION | 11 | 342 | 4.979e-08 | 1.083e-06 |
215 | POSITIVE REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 5 | 28 | 5.559e-08 | 1.203e-06 |
216 | POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 4 | 11 | 5.587e-08 | 1.203e-06 |
217 | RESPONSE TO DRUG | 12 | 431 | 5.651e-08 | 1.212e-06 |
218 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 18 | 1087 | 5.97e-08 | 1.272e-06 |
219 | NEGATIVE REGULATION OF CATABOLIC PROCESS | 9 | 203 | 5.985e-08 | 1.272e-06 |
220 | PROTEIN OLIGOMERIZATION | 12 | 434 | 6.095e-08 | 1.289e-06 |
221 | REGULATION OF CELL ADHESION | 14 | 629 | 6.414e-08 | 1.351e-06 |
222 | APOPTOTIC MITOCHONDRIAL CHANGES | 6 | 57 | 6.522e-08 | 1.367e-06 |
223 | POSITIVE REGULATION OF NIK NF KAPPAB SIGNALING | 5 | 29 | 6.698e-08 | 1.398e-06 |
224 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 9 | 207 | 7.075e-08 | 1.47e-06 |
225 | REGULATION OF TRANSPORT | 23 | 1804 | 7.234e-08 | 1.496e-06 |
226 | LIPID PHOSPHORYLATION | 7 | 99 | 8.06e-08 | 1.659e-06 |
227 | GLYCEROLIPID BIOSYNTHETIC PROCESS | 9 | 211 | 8.335e-08 | 1.705e-06 |
228 | POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 4 | 12 | 8.356e-08 | 1.705e-06 |
229 | REGULATION OF LIPID METABOLIC PROCESS | 10 | 282 | 8.594e-08 | 1.746e-06 |
230 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 22 | 1672 | 8.782e-08 | 1.777e-06 |
231 | REGULATION OF GLUCOSE IMPORT | 6 | 60 | 8.919e-08 | 1.797e-06 |
232 | RENAL SYSTEM PROCESS | 7 | 102 | 9.911e-08 | 1.988e-06 |
233 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 20 | 1395 | 1.004e-07 | 2.004e-06 |
234 | PROTEIN COMPLEX BIOGENESIS | 18 | 1132 | 1.1e-07 | 2.177e-06 |
235 | PROTEIN COMPLEX ASSEMBLY | 18 | 1132 | 1.1e-07 | 2.177e-06 |
236 | MYD88 DEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 5 | 32 | 1.126e-07 | 2.211e-06 |
237 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 5 | 32 | 1.126e-07 | 2.211e-06 |
238 | HEPATOCYTE APOPTOTIC PROCESS | 4 | 13 | 1.204e-07 | 2.343e-06 |
239 | RESPONSE TO COBALT ION | 4 | 13 | 1.204e-07 | 2.343e-06 |
240 | REGULATION OF INFLAMMATORY RESPONSE | 10 | 294 | 1.267e-07 | 2.456e-06 |
241 | REGULATION OF CELLULAR LOCALIZATION | 19 | 1277 | 1.277e-07 | 2.466e-06 |
242 | INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 7 | 106 | 1.293e-07 | 2.485e-06 |
243 | REGULATION OF CYTOKINE PRODUCTION | 13 | 563 | 1.319e-07 | 2.526e-06 |
244 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 18 | 1152 | 1.429e-07 | 2.725e-06 |
245 | RENAL WATER HOMEOSTASIS | 5 | 34 | 1.547e-07 | 2.926e-06 |
246 | CELLULAR RESPONSE TO ALKALOID | 5 | 34 | 1.547e-07 | 2.926e-06 |
247 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 13 | 573 | 1.615e-07 | 3.043e-06 |
248 | TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY | 4 | 14 | 1.68e-07 | 3.153e-06 |
249 | RESPONSE TO CARBOHYDRATE | 8 | 168 | 1.973e-07 | 3.687e-06 |
250 | REGULATION OF CELL ACTIVATION | 12 | 484 | 1.982e-07 | 3.689e-06 |
251 | PROTEIN HETEROOLIGOMERIZATION | 7 | 113 | 2.007e-07 | 3.72e-06 |
252 | PHOSPHOLIPID BIOSYNTHETIC PROCESS | 9 | 235 | 2.085e-07 | 3.85e-06 |
253 | NEGATIVE REGULATION OF NEURON DEATH | 8 | 171 | 2.26e-07 | 4.157e-06 |
254 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 11 | 404 | 2.663e-07 | 4.878e-06 |
255 | CELLULAR RESPONSE TO GLUCAGON STIMULUS | 5 | 38 | 2.759e-07 | 5.034e-06 |
256 | RESPONSE TO CORTICOSTEROID | 8 | 176 | 2.818e-07 | 5.122e-06 |
257 | REGULATION OF CELL DIFFERENTIATION | 20 | 1492 | 2.98e-07 | 5.395e-06 |
258 | CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS | 6 | 74 | 3.168e-07 | 5.714e-06 |
259 | RESPONSE TO RADIATION | 11 | 413 | 3.315e-07 | 5.956e-06 |
260 | LEUKOCYTE ACTIVATION | 11 | 414 | 3.396e-07 | 6.058e-06 |
261 | REGULATION OF AUTOPHAGY | 9 | 249 | 3.398e-07 | 6.058e-06 |
262 | RESPONSE TO KETONE | 8 | 182 | 3.64e-07 | 6.465e-06 |
263 | REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 4 | 17 | 3.962e-07 | 6.957e-06 |
264 | ACTIVATION OF NF KAPPAB INDUCING KINASE ACTIVITY | 4 | 17 | 3.962e-07 | 6.957e-06 |
265 | REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 4 | 17 | 3.962e-07 | 6.957e-06 |
266 | RESPONSE TO METAL ION | 10 | 333 | 4e-07 | 6.996e-06 |
267 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 9 | 258 | 4.579e-07 | 7.98e-06 |
268 | POSITIVE REGULATION OF GLUCOSE TRANSPORT | 5 | 42 | 4.622e-07 | 8.025e-06 |
269 | REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION | 7 | 128 | 4.7e-07 | 8.13e-06 |
270 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 7 | 129 | 4.955e-07 | 8.54e-06 |
271 | INSULIN RECEPTOR SIGNALING PATHWAY | 6 | 80 | 5.05e-07 | 8.671e-06 |
272 | AGING | 9 | 264 | 5.551e-07 | 9.496e-06 |
273 | JNK CASCADE | 6 | 82 | 5.851e-07 | 9.972e-06 |
274 | MULTICELLULAR ORGANISMAL HOMEOSTASIS | 9 | 272 | 7.123e-07 | 1.21e-05 |
275 | RESPONSE TO ALCOHOL | 10 | 362 | 8.561e-07 | 1.448e-05 |
276 | RESPONSE TO GLUCAGON | 5 | 48 | 9.144e-07 | 1.542e-05 |
277 | SINGLE ORGANISM CELL ADHESION | 11 | 459 | 9.387e-07 | 1.577e-05 |
278 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 9 | 282 | 9.618e-07 | 1.61e-05 |
279 | CELL PROLIFERATION | 13 | 672 | 9.831e-07 | 1.64e-05 |
280 | CELLULAR RESPONSE TO OXYGEN LEVELS | 7 | 143 | 9.945e-07 | 1.653e-05 |
281 | LYMPHOCYTE DIFFERENTIATION | 8 | 209 | 1.038e-06 | 1.718e-05 |
282 | POSITIVE REGULATION OF CYTOKINE PRODUCTION | 10 | 370 | 1.043e-06 | 1.722e-05 |
283 | CELLULAR HOMEOSTASIS | 13 | 676 | 1.05e-06 | 1.727e-05 |
284 | REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY | 7 | 145 | 1.092e-06 | 1.789e-05 |
285 | RESPONSE TO GAMMA RADIATION | 5 | 50 | 1.125e-06 | 1.83e-05 |
286 | CELLULAR CHEMICAL HOMEOSTASIS | 12 | 570 | 1.122e-06 | 1.83e-05 |
287 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 21 | 1784 | 1.189e-06 | 1.928e-05 |
288 | POSITIVE REGULATION OF PROTEIN OLIGOMERIZATION | 4 | 22 | 1.201e-06 | 1.933e-05 |
289 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 13 | 684 | 1.198e-06 | 1.933e-05 |
290 | REGULATION OF CELL CELL ADHESION | 10 | 380 | 1.327e-06 | 2.129e-05 |
291 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 6 | 95 | 1.398e-06 | 2.236e-05 |
292 | POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 4 | 23 | 1.45e-06 | 2.31e-05 |
293 | GLYCEROPHOSPHOLIPID METABOLIC PROCESS | 9 | 297 | 1.477e-06 | 2.345e-05 |
294 | REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 7 | 152 | 1.498e-06 | 2.371e-05 |
295 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 8 | 220 | 1.525e-06 | 2.405e-05 |
296 | IMMUNE EFFECTOR PROCESS | 11 | 486 | 1.638e-06 | 2.574e-05 |
297 | REGULATION OF CELL CYCLE | 15 | 949 | 1.643e-06 | 2.574e-05 |
298 | REGULATION OF GLUCOSE TRANSPORT | 6 | 100 | 1.89e-06 | 2.951e-05 |
299 | REGULATION OF HOMOTYPIC CELL CELL ADHESION | 9 | 307 | 1.94e-06 | 3.019e-05 |
300 | PROTEIN COMPLEX SUBUNIT ORGANIZATION | 19 | 1527 | 1.952e-06 | 3.028e-05 |
301 | NEGATIVE REGULATION OF HYDROLASE ACTIVITY | 10 | 397 | 1.966e-06 | 3.039e-05 |
302 | RESPONSE TO STEROID HORMONE | 11 | 497 | 2.034e-06 | 3.133e-05 |
303 | EPITHELIAL CELL APOPTOTIC PROCESS | 4 | 25 | 2.059e-06 | 3.162e-05 |
304 | RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 8 | 233 | 2.34e-06 | 3.582e-05 |
305 | MULTICELLULAR ORGANISMAL WATER HOMEOSTASIS | 5 | 58 | 2.378e-06 | 3.616e-05 |
306 | POSITIVE REGULATION OF PROTEIN IMPORT | 6 | 104 | 2.378e-06 | 3.616e-05 |
307 | CELLULAR RESPONSE TO BIOTIC STIMULUS | 7 | 163 | 2.389e-06 | 3.62e-05 |
308 | MACROMOLECULAR COMPLEX ASSEMBLY | 18 | 1398 | 2.399e-06 | 3.624e-05 |
309 | REGULATION OF BODY FLUID LEVELS | 11 | 506 | 2.418e-06 | 3.641e-05 |
310 | REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 5 | 59 | 2.59e-06 | 3.888e-05 |
311 | REGULATION OF RESPONSE TO WOUNDING | 10 | 413 | 2.797e-06 | 4.185e-05 |
312 | INTRACELLULAR RECEPTOR SIGNALING PATHWAY | 7 | 168 | 2.92e-06 | 4.354e-05 |
313 | RESPONSE TO HYDROGEN PEROXIDE | 6 | 109 | 3.128e-06 | 4.649e-05 |
314 | CELL DEVELOPMENT | 18 | 1426 | 3.175e-06 | 4.705e-05 |
315 | POSITIVE REGULATION OF CELL CELL ADHESION | 8 | 243 | 3.196e-06 | 4.721e-05 |
316 | HOMEOSTASIS OF NUMBER OF CELLS | 7 | 175 | 3.826e-06 | 5.633e-05 |
317 | MEMBRANE ORGANIZATION | 14 | 899 | 4.578e-06 | 6.719e-05 |
318 | REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 6 | 118 | 4.957e-06 | 7.254e-05 |
319 | LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 4 | 31 | 5.037e-06 | 7.346e-05 |
320 | LEUKOCYTE MIGRATION | 8 | 259 | 5.116e-06 | 7.439e-05 |
321 | REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 6 | 122 | 6.011e-06 | 8.713e-05 |
322 | WATER HOMEOSTASIS | 5 | 70 | 6.068e-06 | 8.768e-05 |
323 | MYELOID CELL DIFFERENTIATION | 7 | 189 | 6.35e-06 | 9.148e-05 |
324 | GLYCEROLIPID METABOLIC PROCESS | 9 | 356 | 6.472e-06 | 9.295e-05 |
325 | CELLULAR RESPONSE TO LIPID | 10 | 457 | 6.836e-06 | 9.788e-05 |
326 | PROTEIN AUTOPHOSPHORYLATION | 7 | 192 | 7.041e-06 | 0.0001005 |
327 | PROTEIN KINASE B SIGNALING | 4 | 34 | 7.361e-06 | 0.0001047 |
328 | PHOSPHOLIPID METABOLIC PROCESS | 9 | 364 | 7.739e-06 | 0.0001098 |
329 | NEGATIVE REGULATION OF NECROTIC CELL DEATH | 3 | 11 | 7.854e-06 | 0.0001111 |
330 | POSITIVE REGULATION OF CELL PROLIFERATION | 13 | 814 | 8.034e-06 | 0.0001133 |
331 | REGULATION OF CELLULAR RESPONSE TO STRESS | 12 | 691 | 8.108e-06 | 0.000114 |
332 | REGULATION OF PROTEIN OLIGOMERIZATION | 4 | 35 | 8.288e-06 | 0.0001162 |
333 | RESPONSE TO LIGHT STIMULUS | 8 | 280 | 9.047e-06 | 0.0001264 |
334 | NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS | 9 | 372 | 9.212e-06 | 0.0001283 |
335 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 14 | 957 | 9.347e-06 | 0.0001298 |
336 | B CELL ACTIVATION | 6 | 132 | 9.457e-06 | 0.000131 |
337 | REGULATION OF ENDOTHELIAL CELL DEVELOPMENT | 3 | 12 | 1.044e-05 | 0.0001438 |
338 | REGULATION OF ESTABLISHMENT OF ENDOTHELIAL BARRIER | 3 | 12 | 1.044e-05 | 0.0001438 |
339 | REGULATION OF CYTOPLASMIC TRANSPORT | 10 | 481 | 1.068e-05 | 0.0001466 |
340 | RESPONSE TO INSULIN | 7 | 205 | 1.08e-05 | 0.0001478 |
341 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 9 | 381 | 1.115e-05 | 0.0001521 |
342 | CELLULAR RESPONSE TO RADIATION | 6 | 137 | 1.17e-05 | 0.0001587 |
343 | ACTIVATION OF MAPK ACTIVITY | 6 | 137 | 1.17e-05 | 0.0001587 |
344 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 6 | 138 | 1.22e-05 | 0.000165 |
345 | LIPID MODIFICATION | 7 | 210 | 1.263e-05 | 0.0001703 |
346 | REGULATION OF PROTEIN MATURATION | 5 | 82 | 1.322e-05 | 0.0001777 |
347 | POSITIVE REGULATION OF MACROPHAGE DIFFERENTIATION | 3 | 13 | 1.354e-05 | 0.0001811 |
348 | REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY | 3 | 13 | 1.354e-05 | 0.0001811 |
349 | CELL CELL ADHESION | 11 | 608 | 1.377e-05 | 0.0001836 |
350 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 4 | 40 | 1.426e-05 | 0.0001896 |
351 | PLATELET ACTIVATION | 6 | 142 | 1.435e-05 | 0.0001903 |
352 | GLAND DEVELOPMENT | 9 | 395 | 1.486e-05 | 0.0001964 |
353 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 15 | 1142 | 1.546e-05 | 0.0002038 |
354 | RESPONSE TO ESTROGEN | 7 | 218 | 1.608e-05 | 0.0002108 |
355 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 7 | 218 | 1.608e-05 | 0.0002108 |
356 | RESPONSE TO IONIZING RADIATION | 6 | 145 | 1.617e-05 | 0.0002113 |
357 | INNATE IMMUNE RESPONSE | 11 | 619 | 1.627e-05 | 0.000212 |
358 | POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 5 | 86 | 1.668e-05 | 0.0002167 |
359 | RESPONSE TO ESTRADIOL | 6 | 146 | 1.681e-05 | 0.0002173 |
360 | CELLULAR RESPONSE TO INSULIN STIMULUS | 6 | 146 | 1.681e-05 | 0.0002173 |
361 | REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY | 3 | 14 | 1.719e-05 | 0.0002215 |
362 | REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 6 | 147 | 1.747e-05 | 0.0002246 |
363 | RESPONSE TO TRANSITION METAL NANOPARTICLE | 6 | 148 | 1.816e-05 | 0.0002328 |
364 | POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 5 | 88 | 1.865e-05 | 0.0002384 |
365 | POSITIVE REGULATION OF CELL ACTIVATION | 8 | 311 | 1.933e-05 | 0.0002464 |
366 | EPITHELIAL CELL PROLIFERATION | 5 | 89 | 1.97e-05 | 0.0002505 |
367 | SINGLE ORGANISM CELLULAR LOCALIZATION | 13 | 898 | 2.276e-05 | 0.0002886 |
368 | REGULATION OF LEUKOCYTE DIFFERENTIATION | 7 | 232 | 2.401e-05 | 0.0003036 |
369 | NEGATIVE REGULATION OF CELLULAR CATABOLIC PROCESS | 6 | 156 | 2.446e-05 | 0.0003085 |
370 | RESPONSE TO ANTIBIOTIC | 4 | 47 | 2.73e-05 | 0.0003433 |
371 | SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE | 5 | 96 | 2.844e-05 | 0.0003567 |
372 | NEGATIVE REGULATION OF PROTEOLYSIS | 8 | 329 | 2.889e-05 | 0.0003614 |
373 | ESTABLISHMENT OF LOCALIZATION IN CELL | 18 | 1676 | 2.919e-05 | 0.0003641 |
374 | REGULATION OF LIPID KINASE ACTIVITY | 4 | 48 | 2.97e-05 | 0.0003695 |
375 | INTERSPECIES INTERACTION BETWEEN ORGANISMS | 11 | 662 | 3.019e-05 | 0.0003736 |
376 | SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM | 11 | 662 | 3.019e-05 | 0.0003736 |
377 | NEGATIVE REGULATION OF CELL CYCLE | 9 | 433 | 3.061e-05 | 0.0003778 |
378 | REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 13 | 926 | 3.136e-05 | 0.000386 |
379 | NEGATIVE REGULATION OF ANOIKIS | 3 | 17 | 3.185e-05 | 0.0003911 |
380 | NEGATIVE REGULATION OF PEPTIDASE ACTIVITY | 7 | 245 | 3.401e-05 | 0.0004165 |
381 | POSITIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 4 | 50 | 3.496e-05 | 0.0004269 |
382 | POSITIVE REGULATION OF MITOCHONDRIAL MEMBRANE PERMEABILITY | 3 | 18 | 3.812e-05 | 0.000462 |
383 | REGULATION OF CELL CYCLE PROCESS | 10 | 558 | 3.809e-05 | 0.000462 |
384 | INOSITOL PHOSPHATE MEDIATED SIGNALING | 3 | 18 | 3.812e-05 | 0.000462 |
385 | CELLULAR PROCESS INVOLVED IN REPRODUCTION IN MULTICELLULAR ORGANISM | 7 | 252 | 4.069e-05 | 0.0004917 |
386 | REGULATION OF LIPID CATABOLIC PROCESS | 4 | 52 | 4.086e-05 | 0.0004926 |
387 | ORGANOPHOSPHATE BIOSYNTHETIC PROCESS | 9 | 450 | 4.13e-05 | 0.0004966 |
388 | STRIATED MUSCLE CELL DIFFERENTIATION | 6 | 173 | 4.372e-05 | 0.0005244 |
389 | CELLULAR RESPONSE TO AMINO ACID STIMULUS | 4 | 53 | 4.408e-05 | 0.0005272 |
390 | NEGATIVE REGULATION OF MEIOTIC CELL CYCLE | 3 | 19 | 4.515e-05 | 0.0005387 |
391 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 12 | 823 | 4.561e-05 | 0.0005428 |
392 | REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS | 4 | 54 | 4.747e-05 | 0.000562 |
393 | REGULATION OF MITOCHONDRIAL MEMBRANE POTENTIAL | 4 | 54 | 4.747e-05 | 0.000562 |
394 | REGULATION OF CELL CYCLE ARREST | 5 | 108 | 5.011e-05 | 0.0005903 |
395 | REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 5 | 108 | 5.011e-05 | 0.0005903 |
396 | POSITIVE REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS | 3 | 20 | 5.298e-05 | 0.0006209 |
397 | REGULATION OF MACROPHAGE DIFFERENTIATION | 3 | 20 | 5.298e-05 | 0.0006209 |
398 | REGULATION OF MYELOID CELL DIFFERENTIATION | 6 | 183 | 5.979e-05 | 0.0006972 |
399 | REGULATION OF PROTEIN IMPORT | 6 | 183 | 5.979e-05 | 0.0006972 |
400 | B CELL HOMEOSTASIS | 3 | 21 | 6.164e-05 | 0.0007117 |
401 | NEGATIVE REGULATION OF LIPID CATABOLIC PROCESS | 3 | 21 | 6.164e-05 | 0.0007117 |
402 | CELLULAR RESPONSE TO OXIDATIVE STRESS | 6 | 184 | 6.163e-05 | 0.0007117 |
403 | RESPONSE TO NITRIC OXIDE | 3 | 21 | 6.164e-05 | 0.0007117 |
404 | RESPONSE TO GROWTH FACTOR | 9 | 475 | 6.269e-05 | 0.000722 |
405 | GAMETE GENERATION | 10 | 595 | 6.525e-05 | 0.0007496 |
406 | REGULATION OF MITOCHONDRIAL MEMBRANE PERMEABILITY INVOLVED IN APOPTOTIC PROCESS | 3 | 22 | 7.119e-05 | 0.0008139 |
407 | REGULATION OF PROTEIN HOMODIMERIZATION ACTIVITY | 3 | 22 | 7.119e-05 | 0.0008139 |
408 | DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 10 | 602 | 7.191e-05 | 0.0008201 |
409 | PROTEIN DEPHOSPHORYLATION | 6 | 190 | 7.361e-05 | 0.0008374 |
410 | POSITIVE REGULATION OF CELL ADHESION | 8 | 376 | 7.402e-05 | 0.00084 |
411 | REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 4 | 61 | 7.681e-05 | 0.0008696 |
412 | GLUCOSE METABOLIC PROCESS | 5 | 119 | 7.955e-05 | 0.0008984 |
413 | REGULATION OF B CELL ACTIVATION | 5 | 121 | 8.61e-05 | 0.00097 |
414 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 9 | 498 | 8.998e-05 | 0.001011 |
415 | REGULATION OF ANOIKIS | 3 | 24 | 9.307e-05 | 0.001041 |
416 | T CELL DIFFERENTIATION | 5 | 123 | 9.304e-05 | 0.001041 |
417 | EMBRYO DEVELOPMENT | 12 | 894 | 0.0001006 | 0.001123 |
418 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 5 | 126 | 0.0001043 | 0.001161 |
419 | CELLULAR RESPONSE TO UV | 4 | 66 | 0.0001046 | 0.001162 |
420 | CELLULAR EXTRAVASATION | 3 | 25 | 0.0001055 | 0.001169 |
421 | REGULATION OF CELLULAR COMPONENT BIOGENESIS | 11 | 767 | 0.0001133 | 0.001252 |
422 | MULTICELLULAR ORGANISM REPRODUCTION | 11 | 768 | 0.0001146 | 0.001264 |
423 | CELLULAR COMPONENT DISASSEMBLY | 9 | 515 | 0.000116 | 0.001276 |
424 | DEVELOPMENTAL PROGRAMMED CELL DEATH | 3 | 26 | 0.0001189 | 0.001302 |
425 | NEGATIVE REGULATION OF LIPID TRANSPORT | 3 | 26 | 0.0001189 | 0.001302 |
426 | CELLULAR LIPID METABOLIC PROCESS | 12 | 913 | 0.0001227 | 0.00134 |
427 | GERM CELL DEVELOPMENT | 6 | 209 | 0.0001243 | 0.001355 |
428 | POSITIVE REGULATION OF LEUKOCYTE DIFFERENTIATION | 5 | 131 | 0.0001252 | 0.001362 |
429 | POSITIVE REGULATION OF TYPE I INTERFERON PRODUCTION | 4 | 70 | 0.0001316 | 0.001424 |
430 | PROTEIN LOCALIZATION TO MITOCHONDRION | 4 | 70 | 0.0001316 | 0.001424 |
431 | REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION | 3 | 27 | 0.0001334 | 0.001437 |
432 | DNA CATABOLIC PROCESS | 3 | 27 | 0.0001334 | 0.001437 |
433 | MACROMOLECULE CATABOLIC PROCESS | 12 | 926 | 0.0001401 | 0.001502 |
434 | REGULATION OF PROTEIN TARGETING | 7 | 307 | 0.00014 | 0.001502 |
435 | NEGATIVE REGULATION OF NEURON APOPTOTIC PROCESS | 5 | 135 | 0.0001443 | 0.001543 |
436 | POSITIVE REGULATION OF LEUKOCYTE APOPTOTIC PROCESS | 3 | 28 | 0.000149 | 0.001583 |
437 | RESPONSE TO COPPER ION | 3 | 28 | 0.000149 | 0.001583 |
438 | MODULATION BY SYMBIONT OF HOST CELLULAR PROCESS | 3 | 28 | 0.000149 | 0.001583 |
439 | REGULATION OF HEMOPOIESIS | 7 | 314 | 0.0001609 | 0.001705 |
440 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 4 | 74 | 0.0001633 | 0.001724 |
441 | LIPID BIOSYNTHETIC PROCESS | 9 | 539 | 0.0001634 | 0.001724 |
442 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 9 | 541 | 0.000168 | 0.001765 |
443 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 9 | 541 | 0.000168 | 0.001765 |
444 | POSITIVE REGULATION OF CARBOHYDRATE METABOLIC PROCESS | 4 | 75 | 0.000172 | 0.001803 |
445 | NEGATIVE REGULATION OF B CELL ACTIVATION | 3 | 30 | 0.0001837 | 0.001917 |
446 | REGULATION OF ANION TRANSMEMBRANE TRANSPORT | 3 | 30 | 0.0001837 | 0.001917 |
447 | LYMPHOCYTE COSTIMULATION | 4 | 78 | 0.0002002 | 0.002084 |
448 | NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 8 | 437 | 0.0002081 | 0.002161 |
449 | REGULATION OF LEUKOCYTE APOPTOTIC PROCESS | 4 | 79 | 0.0002103 | 0.00218 |
450 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 10 | 689 | 0.0002167 | 0.002241 |
451 | NEGATIVE REGULATION OF LIPID METABOLIC PROCESS | 4 | 80 | 0.0002208 | 0.002278 |
452 | RESPONSE TO TEMPERATURE STIMULUS | 5 | 148 | 0.0002216 | 0.002281 |
453 | POSITIVE REGULATION OF MYELOID CELL DIFFERENTIATION | 4 | 81 | 0.0002316 | 0.002379 |
454 | REGULATION OF HOMEOSTATIC PROCESS | 8 | 447 | 0.0002425 | 0.002486 |
455 | MUSCLE CELL DIFFERENTIATION | 6 | 237 | 0.0002458 | 0.002513 |
456 | REPRODUCTION | 14 | 1297 | 0.0002518 | 0.002569 |
457 | PEPTIDYL AMINO ACID MODIFICATION | 11 | 841 | 0.0002526 | 0.002571 |
458 | REGULATION OF DNA METABOLIC PROCESS | 7 | 340 | 0.0002615 | 0.002657 |
459 | POSITIVE REGULATION OF CELL CYCLE ARREST | 4 | 85 | 0.0002787 | 0.002826 |
460 | NEGATIVE REGULATION OF PROTEIN PROCESSING | 3 | 35 | 0.0002923 | 0.002944 |
461 | HEXOSE METABOLIC PROCESS | 5 | 157 | 0.0002912 | 0.002944 |
462 | NEGATIVE REGULATION OF PROTEIN MATURATION | 3 | 35 | 0.0002923 | 0.002944 |
463 | REGULATION OF JNK CASCADE | 5 | 159 | 0.0003087 | 0.003103 |
464 | T CELL PROLIFERATION | 3 | 36 | 0.000318 | 0.003179 |
465 | LEUKOCYTE PROLIFERATION | 4 | 88 | 0.0003183 | 0.003179 |
466 | NEGATIVE REGULATION OF TRANSFERASE ACTIVITY | 7 | 351 | 0.0003171 | 0.003179 |
467 | NEGATIVE REGULATION OF KINASE ACTIVITY | 6 | 250 | 0.0003271 | 0.003259 |
468 | REGULATION OF MITOTIC CELL CYCLE | 8 | 468 | 0.0003301 | 0.003282 |
469 | RESPONSE TO HEAT | 4 | 89 | 0.0003324 | 0.003284 |
470 | B CELL DIFFERENTIATION | 4 | 89 | 0.0003324 | 0.003284 |
471 | REGULATION OF GENERATION OF PRECURSOR METABOLITES AND ENERGY | 4 | 89 | 0.0003324 | 0.003284 |
472 | SEXUAL REPRODUCTION | 10 | 730 | 0.0003435 | 0.003387 |
473 | MODULATION BY VIRUS OF HOST MORPHOLOGY OR PHYSIOLOGY | 3 | 37 | 0.0003451 | 0.003395 |
474 | POSITIVE REGULATION OF HEMOPOIESIS | 5 | 163 | 0.0003461 | 0.003398 |
475 | CALCIUM MEDIATED SIGNALING | 4 | 90 | 0.0003469 | 0.003398 |
476 | CELLULAR RESPONSE TO LIGHT STIMULUS | 4 | 91 | 0.0003618 | 0.003537 |
477 | ESTABLISHMENT OF PROTEIN LOCALIZATION TO ORGANELLE | 7 | 361 | 0.0003755 | 0.003663 |
478 | BIOLOGICAL ADHESION | 12 | 1032 | 0.0003795 | 0.003694 |
479 | TISSUE DEVELOPMENT | 15 | 1518 | 0.0003806 | 0.003697 |
480 | ORGANOPHOSPHATE METABOLIC PROCESS | 11 | 885 | 0.0003901 | 0.003781 |
481 | WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY | 3 | 39 | 0.0004038 | 0.00389 |
482 | ERBB2 SIGNALING PATHWAY | 3 | 39 | 0.0004038 | 0.00389 |
483 | SPLEEN DEVELOPMENT | 3 | 39 | 0.0004038 | 0.00389 |
484 | REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS | 4 | 94 | 0.0004094 | 0.003936 |
485 | NEGATIVE REGULATION OF PROTEIN COMPLEX DISASSEMBLY | 5 | 170 | 0.0004197 | 0.004027 |
486 | FC GAMMA RECEPTOR SIGNALING PATHWAY | 4 | 95 | 0.0004262 | 0.004081 |
487 | REGULATION OF MEIOTIC CELL CYCLE | 3 | 40 | 0.0004354 | 0.004149 |
488 | REGULATION OF ACTIVATED T CELL PROLIFERATION | 3 | 40 | 0.0004354 | 0.004149 |
489 | ESTABLISHMENT OF PROTEIN LOCALIZATION TO MEMBRANE | 6 | 264 | 0.000437 | 0.004149 |
490 | NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 9 | 616 | 0.0004368 | 0.004149 |
491 | MYELOID LEUKOCYTE DIFFERENTIATION | 4 | 96 | 0.0004435 | 0.004203 |
492 | MITOTIC SPINDLE ASSEMBLY | 3 | 41 | 0.0004685 | 0.004422 |
493 | MICROTUBULE CYTOSKELETON ORGANIZATION INVOLVED IN MITOSIS | 3 | 41 | 0.0004685 | 0.004422 |
494 | CELLULAR RESPONSE TO ACID CHEMICAL | 5 | 175 | 0.0004791 | 0.004499 |
495 | PROTEIN LOCALIZATION TO MEMBRANE | 7 | 376 | 0.0004789 | 0.004499 |
496 | NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 4 | 98 | 0.0004796 | 0.004499 |
497 | MITOTIC CELL CYCLE | 10 | 766 | 0.0005014 | 0.004694 |
498 | REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION | 4 | 101 | 0.0005376 | 0.005021 |
499 | MYELOID LEUKOCYTE MEDIATED IMMUNITY | 3 | 43 | 0.0005395 | 0.005021 |
500 | REGULATION OF POLYSACCHARIDE METABOLIC PROCESS | 3 | 43 | 0.0005395 | 0.005021 |
501 | NEGATIVE REGULATION OF ORGANELLE ORGANIZATION | 7 | 387 | 0.0005684 | 0.005279 |
502 | CELLULAR RESPONSE TO REACTIVE OXYGEN SPECIES | 4 | 104 | 0.0006004 | 0.005565 |
503 | POSITIVE REGULATION OF INTERLEUKIN 8 PRODUCTION | 3 | 45 | 0.0006171 | 0.005675 |
504 | THYMOCYTE AGGREGATION | 3 | 45 | 0.0006171 | 0.005675 |
505 | MODIFICATION BY SYMBIONT OF HOST MORPHOLOGY OR PHYSIOLOGY | 3 | 45 | 0.0006171 | 0.005675 |
506 | T CELL DIFFERENTIATION IN THYMUS | 3 | 45 | 0.0006171 | 0.005675 |
507 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 10 | 788 | 0.0006247 | 0.005722 |
508 | CIRCULATORY SYSTEM DEVELOPMENT | 10 | 788 | 0.0006247 | 0.005722 |
509 | PEPTIDYL THREONINE MODIFICATION | 3 | 46 | 0.0006584 | 0.006019 |
510 | DEPHOSPHORYLATION | 6 | 286 | 0.0006656 | 0.006073 |
511 | EPITHELIUM DEVELOPMENT | 11 | 945 | 0.0006752 | 0.006148 |
512 | REGULATION OF CERAMIDE BIOSYNTHETIC PROCESS | 2 | 11 | 0.0007269 | 0.006593 |
513 | POSITIVE REGULATION OF HAIR CYCLE | 2 | 11 | 0.0007269 | 0.006593 |
514 | POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS | 3 | 48 | 0.0007462 | 0.006742 |
515 | REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO PLASMA MEMBRANE | 3 | 48 | 0.0007462 | 0.006742 |
516 | REGULATION OF TYPE I INTERFERON PRODUCTION | 4 | 111 | 0.0007669 | 0.006915 |
517 | REPRODUCTIVE SYSTEM DEVELOPMENT | 7 | 408 | 0.000776 | 0.006984 |
518 | REGULATION OF TOLL LIKE RECEPTOR SIGNALING PATHWAY | 3 | 49 | 0.0007928 | 0.007121 |
519 | REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 5 | 197 | 0.0008187 | 0.007322 |
520 | OVULATION CYCLE | 4 | 113 | 0.0008199 | 0.007322 |
521 | POSITIVE REGULATION OF PROTEIN COMPLEX ASSEMBLY | 5 | 197 | 0.0008187 | 0.007322 |
522 | REGULATION OF LYMPHOCYTE MEDIATED IMMUNITY | 4 | 114 | 0.0008474 | 0.007553 |
523 | NEGATIVE REGULATION OF MITOTIC CELL CYCLE | 5 | 199 | 0.0008566 | 0.007621 |
524 | REGULATION OF VITAMIN METABOLIC PROCESS | 2 | 12 | 0.0008702 | 0.007669 |
525 | I KAPPAB PHOSPHORYLATION | 2 | 12 | 0.0008702 | 0.007669 |
526 | REPLICATIVE SENESCENCE | 2 | 12 | 0.0008702 | 0.007669 |
527 | MYELIN MAINTENANCE | 2 | 12 | 0.0008702 | 0.007669 |
528 | POSITIVE REGULATION OF EXECUTION PHASE OF APOPTOSIS | 2 | 12 | 0.0008702 | 0.007669 |
529 | REGULATION OF INTERLEUKIN 12 PRODUCTION | 3 | 51 | 0.0008913 | 0.00784 |
530 | FEMALE SEX DIFFERENTIATION | 4 | 116 | 0.0009042 | 0.007938 |
531 | MONOSACCHARIDE METABOLIC PROCESS | 5 | 202 | 0.000916 | 0.008027 |
532 | POSITIVE REGULATION OF LOCOMOTION | 7 | 420 | 0.0009191 | 0.008039 |
533 | PLASMA MEMBRANE ORGANIZATION | 5 | 203 | 0.0009365 | 0.008175 |
534 | CELLULAR RESPONSE TO IONIZING RADIATION | 3 | 52 | 0.0009434 | 0.008202 |
535 | REGULATION OF T CELL MEDIATED IMMUNITY | 3 | 52 | 0.0009434 | 0.008202 |
536 | NEGATIVE REGULATION OF PHOSPHORYLATION | 7 | 422 | 0.0009449 | 0.008202 |
537 | CELL MOTILITY | 10 | 835 | 0.0009738 | 0.008407 |
538 | LOCALIZATION OF CELL | 10 | 835 | 0.0009738 | 0.008407 |
539 | REGULATION OF IMMUNE EFFECTOR PROCESS | 7 | 424 | 0.0009712 | 0.008407 |
540 | REGULATION OF CELL DEVELOPMENT | 10 | 836 | 0.0009827 | 0.008468 |
541 | REGULATION OF LEUKOCYTE PROLIFERATION | 5 | 206 | 0.0009999 | 0.008536 |
542 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 8 | 554 | 0.0009977 | 0.008536 |
543 | REGULATION OF NITRIC OXIDE BIOSYNTHETIC PROCESS | 3 | 53 | 0.0009974 | 0.008536 |
544 | NEGATIVE REGULATION OF AUTOPHAGY | 3 | 53 | 0.0009974 | 0.008536 |
545 | REGULATION OF TRANSMEMBRANE TRANSPORT | 7 | 426 | 0.0009981 | 0.008536 |
546 | REGULATION OF SPHINGOLIPID BIOSYNTHETIC PROCESS | 2 | 13 | 0.001026 | 0.00868 |
547 | REGULATION OF MEMBRANE LIPID METABOLIC PROCESS | 2 | 13 | 0.001026 | 0.00868 |
548 | POSITIVE REGULATION OF ENDOPLASMIC RETICULUM UNFOLDED PROTEIN RESPONSE | 2 | 13 | 0.001026 | 0.00868 |
549 | REGULATION OF PROTEIN POLYUBIQUITINATION | 2 | 13 | 0.001026 | 0.00868 |
550 | PROTEIN AUTOPROCESSING | 2 | 13 | 0.001026 | 0.00868 |
551 | NEGATIVE REGULATION OF REPRODUCTIVE PROCESS | 3 | 54 | 0.001053 | 0.008862 |
552 | LIPID METABOLIC PROCESS | 12 | 1158 | 0.001051 | 0.008862 |
553 | B CELL RECEPTOR SIGNALING PATHWAY | 3 | 54 | 0.001053 | 0.008862 |
554 | REGULATION OF B CELL PROLIFERATION | 3 | 55 | 0.001111 | 0.009332 |
555 | REGULATION OF ADAPTIVE IMMUNE RESPONSE | 4 | 123 | 0.001124 | 0.009427 |
556 | REGULATION OF FIBROBLAST APOPTOTIC PROCESS | 2 | 14 | 0.001194 | 0.009904 |
557 | NEGATIVE REGULATION OF CELL CYCLE PROCESS | 5 | 214 | 0.001185 | 0.009904 |
558 | INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 2 | 14 | 0.001194 | 0.009904 |
559 | POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 2 | 14 | 0.001194 | 0.009904 |
560 | T CELL MIGRATION | 2 | 14 | 0.001194 | 0.009904 |
561 | DETERMINATION OF ADULT LIFESPAN | 2 | 14 | 0.001194 | 0.009904 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY BINDING | 13 | 47 | 1.02e-21 | 9.477e-19 |
2 | DEATH RECEPTOR BINDING | 9 | 18 | 3.716e-18 | 1.726e-15 |
3 | CYTOKINE RECEPTOR BINDING | 17 | 271 | 1.216e-16 | 3.767e-14 |
4 | KINASE ACTIVITY | 24 | 842 | 1.654e-15 | 3.735e-13 |
5 | ENZYME BINDING | 32 | 1737 | 2.01e-15 | 3.735e-13 |
6 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 7 | 15 | 4.459e-14 | 6.903e-12 |
7 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 24 | 992 | 6.11e-14 | 8.108e-12 |
8 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 17 | 445 | 4.249e-13 | 4.934e-11 |
9 | UBIQUITIN LIKE PROTEIN LIGASE BINDING | 14 | 264 | 7.775e-13 | 8.026e-11 |
10 | PROTEIN HETERODIMERIZATION ACTIVITY | 17 | 468 | 9.542e-13 | 8.864e-11 |
11 | X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 8 | 43 | 3.11e-12 | 2.627e-10 |
12 | PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 9 | 70 | 4.268e-12 | 3.304e-10 |
13 | PROTEIN KINASE ACTIVITY | 18 | 640 | 1.335e-11 | 8.359e-10 |
14 | PHOSPHATIDYLINOSITOL KINASE ACTIVITY | 8 | 51 | 1.334e-11 | 8.359e-10 |
15 | TUMOR NECROSIS FACTOR RECEPTOR BINDING | 7 | 30 | 1.35e-11 | 8.359e-10 |
16 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 9 | 86 | 2.879e-11 | 1.672e-09 |
17 | KINASE BINDING | 17 | 606 | 5.648e-11 | 3.086e-09 |
18 | PROTEASE BINDING | 9 | 104 | 1.632e-10 | 8.422e-09 |
19 | DEATH RECEPTOR ACTIVITY | 6 | 24 | 2.663e-10 | 1.302e-08 |
20 | IDENTICAL PROTEIN BINDING | 21 | 1209 | 1.501e-09 | 6.974e-08 |
21 | ADENYL NUCLEOTIDE BINDING | 23 | 1514 | 2.684e-09 | 1.187e-07 |
22 | PROTEIN DIMERIZATION ACTIVITY | 20 | 1149 | 3.925e-09 | 1.657e-07 |
23 | RECEPTOR BINDING | 22 | 1476 | 9.359e-09 | 3.78e-07 |
24 | PROTEIN PHOSPHATASE BINDING | 8 | 120 | 1.437e-08 | 5.562e-07 |
25 | CYSTEINE TYPE PEPTIDASE ACTIVITY | 9 | 184 | 2.564e-08 | 9.53e-07 |
26 | KINASE REGULATOR ACTIVITY | 9 | 186 | 2.816e-08 | 1.006e-06 |
27 | ENZYME REGULATOR ACTIVITY | 17 | 959 | 5.64e-08 | 1.928e-06 |
28 | PROTEIN DOMAIN SPECIFIC BINDING | 14 | 624 | 5.812e-08 | 1.928e-06 |
29 | RIBONUCLEOTIDE BINDING | 23 | 1860 | 1.265e-07 | 4.052e-06 |
30 | PHOSPHATASE BINDING | 8 | 162 | 1.492e-07 | 4.62e-06 |
31 | MOLECULAR FUNCTION REGULATOR | 19 | 1353 | 3.13e-07 | 9.086e-06 |
32 | PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY | 4 | 16 | 3.038e-07 | 9.086e-06 |
33 | CYSTEINE TYPE ENDOPEPTIDASE REGULATOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 5 | 42 | 4.622e-07 | 1.301e-05 |
34 | PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 4 | 30 | 4.399e-06 | 0.0001202 |
35 | PROTEIN COMPLEX BINDING | 14 | 935 | 7.177e-06 | 0.0001905 |
36 | INSULIN RECEPTOR SUBSTRATE BINDING | 3 | 11 | 7.854e-06 | 0.0002027 |
37 | SIGNAL TRANSDUCER ACTIVITY | 19 | 1731 | 1.212e-05 | 0.0003043 |
38 | PROTEIN KINASE A BINDING | 4 | 42 | 1.737e-05 | 0.0004247 |
39 | PROTEIN KINASE A CATALYTIC SUBUNIT BINDING | 3 | 15 | 2.143e-05 | 0.0005104 |
40 | INTERLEUKIN 1 RECEPTOR BINDING | 3 | 16 | 2.63e-05 | 0.0006109 |
41 | ENDOPEPTIDASE ACTIVITY | 9 | 448 | 3.99e-05 | 0.0009041 |
42 | MACROMOLECULAR COMPLEX BINDING | 16 | 1399 | 4.213e-05 | 0.0009319 |
43 | PROTEIN HOMODIMERIZATION ACTIVITY | 11 | 722 | 6.619e-05 | 0.00143 |
44 | ENZYME INHIBITOR ACTIVITY | 8 | 378 | 7.68e-05 | 0.001622 |
45 | CAMP BINDING | 3 | 23 | 8.165e-05 | 0.001649 |
46 | CYSTEINE TYPE ENDOPEPTIDASE INHIBITOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 3 | 23 | 8.165e-05 | 0.001649 |
47 | PROTEIN SERINE THREONINE PHOSPHATASE ACTIVITY | 4 | 64 | 9.274e-05 | 0.001833 |
48 | PEPTIDASE REGULATOR ACTIVITY | 6 | 214 | 0.0001414 | 0.002737 |
49 | PROTEIN PHOSPHATASE 2A BINDING | 3 | 28 | 0.000149 | 0.002826 |
50 | CYCLIC NUCLEOTIDE BINDING | 3 | 36 | 0.000318 | 0.005908 |
51 | KINASE INHIBITOR ACTIVITY | 4 | 89 | 0.0003324 | 0.006055 |
52 | PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 5 | 178 | 0.0005177 | 0.009248 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | MEMBRANE MICRODOMAIN | 19 | 288 | 5.919e-19 | 3.456e-16 |
2 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 17 | 237 | 1.267e-17 | 3.7e-15 |
3 | CATALYTIC COMPLEX | 27 | 1038 | 1.652e-16 | 3.216e-14 |
4 | PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX | 8 | 20 | 2.891e-15 | 4.22e-13 |
5 | MEMBRANE PROTEIN COMPLEX | 25 | 1020 | 1.17e-14 | 1.366e-12 |
6 | TRANSFERASE COMPLEX | 18 | 703 | 6.226e-11 | 6.06e-09 |
7 | PROTEIN KINASE COMPLEX | 8 | 90 | 1.448e-09 | 1.208e-07 |
8 | MEMBRANE REGION | 20 | 1134 | 3.135e-09 | 2.289e-07 |
9 | PLASMA MEMBRANE PROTEIN COMPLEX | 14 | 510 | 4.622e-09 | 2.999e-07 |
10 | CILIARY BASE | 5 | 23 | 1.931e-08 | 1.128e-06 |
11 | CD40 RECEPTOR COMPLEX | 4 | 11 | 5.587e-08 | 2.966e-06 |
12 | CYTOSOLIC PART | 9 | 223 | 1.336e-07 | 6.503e-06 |
13 | MITOCHONDRION | 21 | 1633 | 2.77e-07 | 1.244e-05 |
14 | RECEPTOR COMPLEX | 9 | 327 | 3.251e-06 | 0.0001356 |
15 | EXTRINSIC COMPONENT OF MEMBRANE | 8 | 252 | 4.181e-06 | 0.0001628 |
16 | IKAPPAB KINASE COMPLEX | 3 | 11 | 7.854e-06 | 0.0002867 |
17 | PHOSPHATASE COMPLEX | 4 | 48 | 2.97e-05 | 0.00102 |
18 | PLASMA MEMBRANE RECEPTOR COMPLEX | 6 | 175 | 4.662e-05 | 0.001513 |
19 | OUTER MEMBRANE | 6 | 190 | 7.361e-05 | 0.002263 |
20 | INTRINSIC COMPONENT OF PLASMA MEMBRANE | 17 | 1649 | 8.527e-05 | 0.00249 |
21 | MITOCHONDRIAL ENVELOPE | 10 | 691 | 0.0002218 | 0.006168 |
22 | PLASMA MEMBRANE RAFT | 4 | 86 | 0.0002915 | 0.007738 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | hsa04210_Apoptosis | 74 | 89 | 7.651e-195 | 1.354e-192 | |
2 | hsa04380_Osteoclast_differentiation | 25 | 128 | 3.237e-37 | 2.864e-35 | |
3 | hsa04620_Toll.like_receptor_signaling_pathway | 23 | 102 | 8.817e-36 | 5.202e-34 | |
4 | hsa04722_Neurotrophin_signaling_pathway | 24 | 127 | 2.514e-35 | 1.112e-33 | |
5 | hsa04660_T_cell_receptor_signaling_pathway | 22 | 108 | 3.882e-33 | 1.374e-31 | |
6 | hsa04662_B_cell_receptor_signaling_pathway | 20 | 75 | 9.615e-33 | 2.836e-31 | |
7 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 22 | 136 | 9.521e-31 | 2.408e-29 | |
8 | hsa04010_MAPK_signaling_pathway | 26 | 268 | 2.202e-30 | 4.871e-29 | |
9 | hsa04370_VEGF_signaling_pathway | 17 | 76 | 2.044e-26 | 4.019e-25 | |
10 | hsa04910_Insulin_signaling_pathway | 19 | 138 | 3.741e-25 | 6.622e-24 | |
11 | hsa04062_Chemokine_signaling_pathway | 19 | 189 | 1.85e-22 | 2.978e-21 | |
12 | hsa04914_Progesterone.mediated_oocyte_maturation | 14 | 87 | 1.074e-19 | 1.584e-18 | |
13 | hsa04510_Focal_adhesion | 17 | 200 | 6.994e-19 | 9.523e-18 | |
14 | hsa04973_Carbohydrate_digestion_and_absorption | 11 | 44 | 5.694e-18 | 7.199e-17 | |
15 | hsa04920_Adipocytokine_signaling_pathway | 12 | 68 | 1.597e-17 | 1.884e-16 | |
16 | hsa04622_RIG.I.like_receptor_signaling_pathway | 12 | 71 | 2.783e-17 | 3.079e-16 | |
17 | hsa04150_mTOR_signaling_pathway | 11 | 52 | 4.382e-17 | 4.563e-16 | |
18 | hsa04664_Fc_epsilon_RI_signaling_pathway | 12 | 79 | 1.088e-16 | 1.07e-15 | |
19 | hsa04012_ErbB_signaling_pathway | 12 | 87 | 3.682e-16 | 3.43e-15 | |
20 | hsa04621_NOD.like_receptor_signaling_pathway | 10 | 59 | 1.39e-14 | 1.23e-13 | |
21 | hsa04630_Jak.STAT_signaling_pathway | 13 | 155 | 1.522e-14 | 1.282e-13 | |
22 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 11 | 95 | 5.001e-14 | 4.024e-13 | |
23 | hsa04115_p53_signaling_pathway | 10 | 69 | 7.305e-14 | 5.621e-13 | |
24 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 8 | 42 | 2.539e-12 | 1.872e-11 | |
25 | hsa04070_Phosphatidylinositol_signaling_system | 8 | 78 | 4.537e-10 | 3.212e-09 | |
26 | hsa04720_Long.term_potentiation | 7 | 70 | 7.067e-09 | 4.811e-08 | |
27 | hsa04670_Leukocyte_transendothelial_migration | 8 | 117 | 1.177e-08 | 7.713e-08 | |
28 | hsa04623_Cytosolic_DNA.sensing_pathway | 6 | 56 | 5.852e-08 | 3.7e-07 | |
29 | hsa04310_Wnt_signaling_pathway | 8 | 151 | 8.666e-08 | 5.289e-07 | |
30 | hsa04114_Oocyte_meiosis | 7 | 114 | 2.132e-07 | 1.258e-06 | |
31 | hsa04810_Regulation_of_actin_cytoskeleton | 8 | 214 | 1.239e-06 | 7.077e-06 | |
32 | hsa04020_Calcium_signaling_pathway | 7 | 177 | 4.124e-06 | 2.281e-05 | |
33 | hsa00562_Inositol_phosphate_metabolism | 4 | 57 | 5.88e-05 | 0.0003154 | |
34 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 5 | 168 | 0.0003976 | 0.00207 | |
35 | hsa04962_Vasopressin.regulated_water_reabsorption | 3 | 44 | 0.0005775 | 0.00292 | |
36 | hsa04742_Taste_transduction | 3 | 52 | 0.0009434 | 0.004638 | |
37 | hsa04340_Hedgehog_signaling_pathway | 3 | 56 | 0.001171 | 0.005601 | |
38 | hsa04360_Axon_guidance | 4 | 130 | 0.00138 | 0.006427 | |
39 | hsa04976_Bile_secretion | 3 | 71 | 0.00232 | 0.01053 | |
40 | hsa04971_Gastric_acid_secretion | 3 | 74 | 0.002611 | 0.01155 | |
41 | hsa04640_Hematopoietic_cell_lineage | 3 | 88 | 0.00426 | 0.01839 | |
42 | hsa04970_Salivary_secretion | 3 | 89 | 0.004397 | 0.01853 | |
43 | hsa04540_Gap_junction | 3 | 90 | 0.004536 | 0.01867 | |
44 | hsa04912_GnRH_signaling_pathway | 3 | 101 | 0.006251 | 0.02459 | |
45 | hsa04916_Melanogenesis | 3 | 101 | 0.006251 | 0.02459 | |
46 | hsa04270_Vascular_smooth_muscle_contraction | 3 | 116 | 0.00914 | 0.03517 | |
47 | hsa04530_Tight_junction | 3 | 133 | 0.01322 | 0.04979 | |
48 | hsa04120_Ubiquitin_mediated_proteolysis | 3 | 139 | 0.01487 | 0.05484 | |
49 | hsa04110_Cell_cycle | 2 | 128 | 0.08151 | 0.2944 | |
50 | hsa04740_Olfactory_transduction | 3 | 388 | 0.1735 | 0.6023 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | UCA1 |
hsa-miR-1224-5p;hsa-miR-129-5p;hsa-miR-140-5p;hsa-miR-16-1-3p;hsa-miR-186-5p;hsa-miR-204-5p;hsa-miR-299-3p;hsa-miR-3065-5p;hsa-miR-339-5p;hsa-miR-455-5p;hsa-miR-582-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-628-3p;hsa-miR-7-1-3p | 15 | IL1RAP | Sponge network | 1.481 | 0.28957 | 0.24 | 0.6772 | 0.623 |
2 | HCG11 |
hsa-miR-148b-3p;hsa-miR-16-2-3p;hsa-miR-186-5p;hsa-miR-200b-3p;hsa-miR-3607-3p;hsa-miR-3613-3p;hsa-miR-376a-3p;hsa-miR-376b-3p;hsa-miR-501-5p;hsa-miR-590-3p;hsa-miR-7-1-3p | 11 | PIK3CA | Sponge network | -0.31 | 0.48859 | -0.202 | 0.54123 | 0.543 |
3 | RFPL1S |
hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-192-5p;hsa-miR-196b-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-215-5p;hsa-miR-224-5p;hsa-miR-33a-5p;hsa-miR-34a-5p;hsa-miR-429;hsa-miR-96-5p | 17 | BCL2 | Sponge network | -0.457 | 0.43621 | -1.629 | 0.00261 | 0.539 |
4 | HCG11 |
hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-215-5p;hsa-miR-29a-5p;hsa-miR-29b-3p;hsa-miR-3065-5p;hsa-miR-455-5p | 14 | BCL2 | Sponge network | -0.31 | 0.48859 | -1.629 | 0.00261 | 0.503 |
5 | CECR7 | hsa-miR-182-5p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-215-5p;hsa-miR-224-5p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-429 | 11 | BCL2 | Sponge network | -0.527 | 0.47624 | -1.629 | 0.00261 | 0.495 |
6 | MIR155HG | hsa-miR-128-3p;hsa-miR-129-5p;hsa-miR-148b-3p;hsa-miR-148b-5p;hsa-miR-181c-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-3065-5p;hsa-miR-33b-5p;hsa-miR-375 | 10 | PRKX | Sponge network | -1.955 | 0.00055 | -0.87 | 0.01822 | 0.489 |
7 | RFPL1S |
hsa-miR-106b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-429;hsa-miR-96-5p | 11 | PIK3R1 | Sponge network | -0.457 | 0.43621 | -0.508 | 0.16815 | 0.458 |
8 | HCP5 | hsa-miR-128-3p;hsa-miR-129-5p;hsa-miR-148b-3p;hsa-miR-148b-5p;hsa-miR-181c-5p;hsa-miR-330-3p;hsa-miR-33b-5p;hsa-miR-375;hsa-miR-409-3p;hsa-miR-495-3p;hsa-miR-539-5p;hsa-miR-96-5p | 12 | PRKX | Sponge network | -0.577 | 0.20814 | -0.87 | 0.01822 | 0.446 |
9 | HCG11 |
hsa-miR-106b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-22-5p;hsa-miR-222-3p;hsa-miR-29b-3p;hsa-miR-3065-5p;hsa-miR-590-3p | 12 | PIK3R1 | Sponge network | -0.31 | 0.48859 | -0.508 | 0.16815 | 0.423 |
10 | DIO3OS |
hsa-miR-1224-5p;hsa-miR-129-5p;hsa-miR-139-5p;hsa-miR-16-1-3p;hsa-miR-186-5p;hsa-miR-204-5p;hsa-miR-299-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-301a-3p;hsa-miR-3607-3p;hsa-miR-3613-3p;hsa-miR-455-5p;hsa-miR-582-5p | 14 | IL1RAP | Sponge network | 1.18 | 0.0997 | 0.24 | 0.6772 | 0.366 |
11 | HCG11 |
hsa-miR-141-3p;hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-16-5p;hsa-miR-200a-3p;hsa-miR-29b-2-5p;hsa-miR-340-5p;hsa-miR-369-3p;hsa-miR-501-5p;hsa-miR-590-3p;hsa-miR-7-1-3p | 11 | IRAK3 | Sponge network | -0.31 | 0.48859 | -0.545 | 0.29063 | 0.336 |
12 | PVT1 | hsa-miR-1224-5p;hsa-miR-129-5p;hsa-miR-139-5p;hsa-miR-204-5p;hsa-miR-299-3p;hsa-miR-301a-3p;hsa-miR-361-5p;hsa-miR-455-5p;hsa-miR-543;hsa-miR-582-5p | 10 | IL1RAP | Sponge network | 0.67 | 0.32654 | 0.24 | 0.6772 | 0.334 |
13 | EGOT | hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-16-5p;hsa-miR-29b-2-5p;hsa-miR-3200-3p;hsa-miR-324-5p;hsa-miR-33b-5p;hsa-miR-340-5p;hsa-miR-369-3p;hsa-miR-421;hsa-miR-7-1-3p | 11 | IRAK3 | Sponge network | -1.196 | 0.1622 | -0.545 | 0.29063 | 0.332 |
14 | DIO3OS |
hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-16-5p;hsa-miR-29b-2-5p;hsa-miR-324-5p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-501-5p;hsa-miR-582-5p;hsa-miR-589-3p | 10 | IRAK3 | Sponge network | 1.18 | 0.0997 | -0.545 | 0.29063 | 0.33 |
15 | H19 | hsa-miR-103a-2-5p;hsa-miR-128-3p;hsa-miR-129-5p;hsa-miR-148b-3p;hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-181c-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-29b-3p;hsa-miR-495-3p;hsa-miR-539-5p | 12 | PRKX | Sponge network | -0.02 | 0.98077 | -0.87 | 0.01822 | 0.325 |
16 | UCA1 |
hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-16-5p;hsa-miR-29b-2-5p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-340-5p;hsa-miR-501-5p;hsa-miR-582-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-628-3p;hsa-miR-7-1-3p | 13 | IRAK3 | Sponge network | 1.481 | 0.28957 | -0.545 | 0.29063 | 0.31 |
17 | HCG11 |
hsa-miR-16-1-3p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-19b-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-301a-3p;hsa-miR-3065-5p;hsa-miR-3607-3p;hsa-miR-3613-3p;hsa-miR-362-3p;hsa-miR-455-5p;hsa-miR-590-3p;hsa-miR-664a-3p;hsa-miR-7-1-3p | 15 | IL1RAP | Sponge network | -0.31 | 0.48859 | 0.24 | 0.6772 | 0.307 |
18 | FAM66C | hsa-miR-15b-3p;hsa-miR-17-5p;hsa-miR-196b-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-20a-5p;hsa-miR-215-5p;hsa-miR-224-5p;hsa-miR-34a-5p | 10 | BCL2 | Sponge network | -0.537 | 0.25424 | -1.629 | 0.00261 | 0.251 |